Oncology Clinica l Development & Medical Affairs
PKC412, MIDOSTAURIN
Protocol CPKC412AUS23 / [STUDY_ID_REMOVED]
A Phase II, randomized trial of standard of care, w ith or 
without midostaurin to prev ent relapse follow ing allogeneic 
hematopoietic stem cell transplantation in patients w ith 
FLT3- ITD mutated acute my eloid leukemia
Authors
Document type Amended Protocol Version
EUDRACT number Not applicable
Version number 02 (Clean )
Development phase II
Document status Final
Release date 02-Jul-2015
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Template version 15- Feb-2012
 

[COMPANY_001] Confidential Page 2
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Table of contents
Table of contents ................................................................................................................. [ADDRESS_277791] of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
Amendment 2 .................................................................................................................... 11
Amendment 1 .................................................................................................................... 14
Protocol summary :
............................................................................................................. 20
1Background ........................................................................................................................ 24
1.1 Overview of acute my eloid leukemia, epi[INVESTIGATOR_111750] ......... 24
1.1.1 FMS -like ty rosine kinase 3 mutations ................................................... 24
1.1.2 Allogeneic hematopoietic stem cell transplantation in AML ............... 25
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. [ADDRESS_277792] aurin ....................................................................... 28
2Rationale ................................ ................................ ................................ ............................ 31
2.1 Study  rationale and purpose ................................................................................... 31
2.2 Rationale for the stud y design ............................................................................... 32
2.3 Rationale for dose and regimen selection .............................................................. 32
2.4 Rationale for choice of drugs ................................................................................. 33
3Objectives and endpoints ................................................................................................... 33
4Study  design ...................................................................................................................... 36
4.1 Description of stud y design ................................................................................... 36
4.2 Definition of end of the study ................................................................................ 37
4.3 Early study termination .......................................................................................... 37
5Population .......................................................................................................................... 37
5.1 Patient population .................................................................................................. 37
5.2 Inclusion criteria .................................................................................................... 38
5.3 Exclusion criteria ................................................................................................... 39
6Treatment ........................................................................................................................... 40
6.1 Study  treatment ...................................................................................................... 40
6.1.1 Midostaurin dosing regimen ................................................................. 41
6.1.2 Treatment duration ................................................................................ 41
6.2 Dose escalation guidelines ..................................................................................... 41
6.3 Dose modifications ................................................................................................ 41
6.3.1 Dose modification and dose delay ........................................................ 41
 

[COMPANY_001] Confidential Page 3
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
6.3.2 Follow -up for toxicities ......................................................................... 46
6.3.3 Anticipated risks and safety  concerns of the study drug ....................... 46
6.4
Concomitant medications ...................................................................................... 46
6.4.1 Permitted concomitant therap y
............................................................. 46
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 48
6.5 Patient numbering, treatment assignment or randomization ................................. 50
6.5.1
Patient numbering ................................................................................. 50
6.5.2
Treatment assignment or randomization............................................... 50
6.5.3 Treatment blinding ................................................................................ 51
6.6 Study  drug preparation and dispensation ............................................................... 51
6.6.1 Study  drug packaging and labeling ....................................................... 51
6.6.2 Drug supply  and storage ........................................................................ 52
6.6.3 Study  drug compliance and accountabilit y
........................................... 52
6.6.4 Disposal and destruction ....................................................................... 53
7Visit schedule and assessments ......................................................................................... 53
7.1 Study  flow and visit schedule ................................................................................ 53
7.1.1 Screening ............................................................................................... 57
7.1.2 Treatment and stud y period ................................................................... 58
7.1.3
End of treatment visit including study  completion and premature 
withdrawal ............................................................................................. 59
7.1.4
Follow up for survival and RFS............................................................ 60
7.2 Assessment ty pes................................................................................................... 61
7.2.1 Efficacy  assessments ............................................................................. 61
7.2.2 Safety  and tolerability  assessments ....................................................... 62
7.2.3 Pharmacokinetics (PK) .......................................................................... [ADDRESS_277793] abnormalities ................................................................ 74
8.2 Serious adverse events ........................................................................................... 74
8.2.1
Definitions............................................................................................. 74
8.2.2
Reporting............................................................................................... 75
8.3 Emergency  unblinding of treatment assignment ................................................... 76
8.4 Pregnancy  prevention requirements ...................................................................... 76
 

[COMPANY_001] Confidential Page 4
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
8.5 Pregnancy  reporting ................................ ................................ ............................... 76
8.6 Warnings and precautions ...................................................................................... 76
8.7 Data Monitoring Committee .................................................................................. 77
8.8 Independent Review committee ............................................................................ 77
9Data collection and management ....................................................................................... 77
9.1 Data confidentiality ............................................................................................... 77
9.2 Site monitoring ...................................................................................................... 78
9.3
Data collection....................................................................................................... 78
9.4 Database management and quality  control ............................................................ 78
10
Statistical methods and data analysis................................................................................ 79
10.1 Analy sis sets .......................................................................................................... 79
10.1.1 Full Anal ysis Set ................................................................................... 79
10.1.2 Safety  Set
.............................................................................................. 79
10.1.3
Per-Protocol Set .................................................................................... 79
10.1.4 Pharmacokinetic Analy sis Set ............................................................... 80
10.2 Patient demographics/other baseline characteristics ............................................. 80
10.3 Treatments (stud y treatment, concomitant therapi[INVESTIGATOR_014], compliance)
....................... 80
10.3.1 Study  medication ................................................................................... 80
10.3.2 Concomitant therapi[INVESTIGATOR_014] ........................................................................... 80
10.4 Primary  objective ................................................................................................... 80
10.4.1 Relapse free survival ............................................................................. 80
10.4.2 Statistical hy pothesis, model, and method of analy sis.......................... 81
10.4.3 Handling of missing 
values/censoring/discontinuations ....................... 81
10.4.4 Supportive analy ses............................................................................... 81
10.5 Secondary  objectives ............................................................................................. 81
10.5.1 Key secondary  efficacy  evaluation ....................................................... 81
10.5.2 Safety  objectives ................................................................................... 82
10.5.3 Pharmacokinetics .................................................................................. 84
10.5.4 Biomarkers ............................................................................................ 84
.84
10.7 Interim anal ysis...................................................................................................... 84
10.8
Sample size calculation.......................................................................................... 84
11Ethical considerations and administrative procedures ...................................................... 85
11.1 Regulatory
 and ethical compliance ........................................................................ 85
11.2 Responsibilities of the investigator and IRB/ IEC/REB ......................................... 85
11.3 Informed consent procedures
................................................................................. 85
 

[COMPANY_001] Confidential Page 5
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
11.[ADDRESS_277794] keepi[INVESTIGATOR_5304]
....................... 86
11.7 Confidentiality  of study  documents and patient records ....................................... 87
11.8
Audits and inspections........................................................................................... 87
11.9 Financial disclosures .............................................................................................. 87
12Protocol adherence ............................................................................................................ 88
12.1 Amendments to the protocol .................................................................................. 88
13References (available upon request) .................................................................................. 89
 

[COMPANY_001] Confidential Page 6
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
List of figures
Figure [ADDRESS_277795] of tables
Table 3
-1 Objectives and related endpoints .......................................................... 34
Table 6
-1 Dose and drug schedule ........................................................................ 41
Table 6
-2 Criteria for interruption and re-initiation of midostaurin treatment...... 43
Table 6-3 Preparation and dispensing ................................................................... 51
Table 6
-4 Packaging and labeling ......................................................................... 52
Table 6
-5 Supply  and sto rage of study  treatments ................................................ 52
Table 7
-1 Visit evaluation schedule ...................................................................... 54
Table 7
-2 Treatment visit frequency and windows ............................................... 59
Table 7
-3 Follow up assessment frequency  and windows .................................... 61
Table 7
-4 Bone marrow collection plan ................................................................ 62
Table 7
-5 ECOG Performance Status .................................................................... 63
Table 7
-6 Local clinical laboratory  parameters collection plan ............................ 64
Table 7-7 ECG collection plan .............................................................................. 66
Table 7
-8 Routine pharmacokinetic blood collection log ..................................... 67
68
70
71
72
 

[COMPANY_001] Confidential Page 7
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
List of abbreviations
AE Adverse event
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
AML Acute Myeloid Leukemia
ASM Aggressive Sy stemic Mastocytosis
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
BR Blast reduction
b.i.d. bis in die / twice a day
BM Bone Marrow
CBC Complete Blood Count
CRF Case Report/Record Form
CR Complete Remission/Response
CRO Contract Research Organization
CSR Clinical Study Report
CTCAE Common Terminology Criteria for Adverse Events v4.0
CYP3A4 Cytochrome P 450 3A4
DLT Dose Limiting Toxicity
DNA Deoxyribonucleic acid
DSE&E Drug Safety and Epi[INVESTIGATOR_230724]/Record Form
ECG Electrocardiogram
FLT3 -ITD fms-like ty rosine kinase 3, internal tandem duplication
FAS Full Analysis Set
GVHD Graft versus host disease
HSCT Hematopoietic Stem Cell Transplant
HR Hazard Ratio
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IRB Institutional Review Board
IWRS Interactive Web Response System
kg Kilograms
KM Kaplan -Meier
MA Medical Affairs
MCL Mast cell leukemia
MDS Myelody splastic syndrome
mg Milligrams
MTD Maximum Tolerated Dose
MUGA Multi Gated Acquisition scan
NRM Non-relapse mortality
OS Overall Survival
 

[COMPANY_001] Confidential Page 8
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
p.o. per os /by [CONTACT_1966]/orally
PPS Per Protocol Set
PD Pharmacodynamics
PFS Progression Free Survival
PHI Protected Health Information
Pgp P-glycoprotein
PK Pharmacokinetics
PR Partial Response
REB Research Ethics Board
RFS Relapse Free Survival
SS Safety Set
SAE Serious adverse event
SOP Standard Operating Procedure
SOC Standard of Care
TD-PCR Tandem Duplication Poly merase Chain Reaction
t.i.d. Three times per day
TKD Tyrosine Kinase Domain
TRM Treatment Related Mortality
ULN Upper limit of normal
WT Wild-type
 

[COMPANY_001] Confidential Page 9
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Glossary  of terms
Assessment Aprocedure used to generate data required by [CONTACT_37214] A group of newly enrolled patients treated at a specific dose and 
regimen (i.e. treatment group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days, for this study c ycles are 28 days in 
length
Complete Remission Patients are considered to be in Complete Remission (CR) when the 
following levels are detected in the Peripheral Blood (PB); ANC ≥ 
1000/uL; Platelet count ≥ 100K and no circulating leukemic 
myeloblasts in peripheral blood and Bone Marrow (BM) has adequate 
cellularity, BM blast count ≤ 5% and no auer rods detected
Dose level The dose of drug given to the patient (total daily or weekly  etc.)
Enrollment Point/time o f patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)
Investigational drug The study drug, midostaurin in this case, whose properties are being 
tested in the study; this definition is consistent with US CFR 21 
Section 312.3 and is synony mous with “investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study. This also 
includes approved drugs used outside of their indication/approved 
dosage, or that are tested in a fixed combination. Investigational 
treatment generally does not include other study treatments 
administered as concomitant background therapy required or allowed 
by [CONTACT_230753]/dosage
Other study treatment Any drug administered to the patient as part of the required study 
procedures that was not included in the investigational treatment
Patient Number A unique identifying number assigned to each patient/subj ect/healthy 
volunteer who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller 
functional segments such as screening, baseline, titration, washout, 
etc.
Premature patient withdrawal Point/time when the patient exit s from the study prior to the planned 
completion of all study treatment administration and/or assessments; 
at this time all study treatment administration is discontinued and no 
further assessments are planned, unless the patient will be followed 
for progr ession and/or survival
Randomization number A unique treatment identification code assigned to each randomized 
patient, corresponding to a specific treatment arm assignment
Relapse Recurrence of disease ( ≥ 5% blasts in peripheral blood or bone 
marrow) applies to patient transplanted after achieving a complete 
remission and for whom relapse of disease can be recorded.
Study treatment Includes any drug or combination of drugs in any study arm 
administered to the patient (subject) as part of the required study  
procedures, including placebo and active drug run -ins.
In specific examples, it is important to judge investigational treatment 
component relationship relative to a study treatment combination; 
study treatment in this case refers to the investigation al and non -
investigational treatments in combination.
 

[COMPANY_001] Confidential Page 10
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for 
any reason; may  or may  not also be the point/time of premature 
patient withdrawal
Variable Identifier used in the data analysis; derived directly or indirectly from 
data collected using specified assessments at specified timepoints
 

[COMPANY_001] Confidential Page 11
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Amendment 2
Amendment rationale
This study  is activel y enrolling in 23 centers with 35/[ADDRESS_277796], “Day 30- [ADDRESS_277797]”
Section 5.2: Inclusion Criteria:
Change to inclusion criteria 1: Age changed from between 18 and 60 to “between 18 and 70 
years of age”
Section 5.3: Exclusion Criteria :
Updated language in exclusion criteria 10: “Patient requires treatment with (a) strong 
CYP3A4 inhibitors other than those required for GVH or infection prophy laxis or treatment 
or (b) moderate or strong CYP3A4 inducer regardless of proph ylaxis or treatme nt.”
Section 6.2: Update Criteria for interruption and re- initiation of Midostaurin treatment
Update dNausea and Vomiting language from:
Grade [ADDRESS_277798] anti -emetic therapy, hold midostaurin for 3 
days (6 doses) and r esume midostaurin as tolerated;
Grade 3 or 4 If this develops despi[INVESTIGATOR_230725] -emetic therapy, hold midostaurin until 
recover y to Grade 2 (or at least 3 day s) then restart. If this is felt to be related to study 
drug and the re -challange results in a subsequent Grade 3 or 4 toxicity then the patient 
should be discontinued from treatment.
Updated Nausea and Vomiting language to:
Grade 2 If this develops despi[INVESTIGATOR_230725]-emetic therapy, hold midostaurin for 3 
days (6 doses) and resume midostaurin as tolerated
Grade 3 or 4 If this develops despi[INVESTIGATOR_230725] -emetic therapy, hold midostaurin until 
recover y to Grade 2 (or at least 3 day s) then restart. If this is felt to be related to study 
drug and the re -challange results in a subsequent Grade 3 or 4 toxicity t hen the 
midostaurin dose may  be reduced (e.g from 50mg b.i.d to 25mg b.i.d).
In the event of additional toxicity requiring dose modification refer to “Grade 3 or 4 -
Other adverse events (Non -Hematologic) below.
Section 6.3.1: Added language referencing “the dose modification table”
 

[COMPANY_001] Confidential Page 12
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Section [IP_ADDRESS]: Concomitant anti -infective prophylaxis and treatment:
Corrected the language to allow use of the suggested prophy laxis and spelling errors. 
Gramatical changes applied.
Section 6.6.4 : Disposal and destruction:
Updated language to, “The study  drug supply  should be destroy ed at the designated [COMPANY_001] 
facility  or third party, as appropriate. On site disposal or destruction is permitted upon 
[COMPANY_001] review and agreement with the local p olicy /SOP.”
Table 7 -1: Visit evaluation schedule
Updated language to allow CT scan, Chest x- ray/CT Scan
Removed, 
Section [IP_ADDRESS]: Radiological examinations
Updated language to allow CT scan: “A screening chest image; Chest x-ray (CXR) or CT 
scan must be performed to assess study  eligibility. If a CXR or CT scan was done within 14 
days of screening assessments then it does not need to be repeated.”
Section [IP_ADDRESS].2: Cardiac imaging -MUGA (multiple gated acquisition) scan or 
echocardiogram
Added: “C ycle 3, 6 and at the EOT visit”
Table 7 -7: ECG collection plan
Removed, “placebo”
Table 7 -8: Routine pharmacokinetic blood collection log
Removed, “Unscheduled”
 

[COMPANY_001] Confidential Page 13
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Section 8.8: Independent Review committee
Updated language to allow for additional patients at the discretion of the I RC
Section 9.4: Database management and quality control
Removed language, “by [CONTACT_230754] .”
 

[COMPANY_001] Confidential Page 14
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Amendment [ADDRESS_277799] been randomized into 
the study . During the study  start-up phase, feedback has been received from various 
investigators and EC/I RBs on areas where clarifications/Amendments could be made to the 
protocol -these have been incorporated in the current amendment.
The changes proposed in this amendment will influence the eligibility  criteria, drug suppl y 
and storage, data monitoring and capturing, addition of assumption for study  size calculation 
and change of stud y steering co mmittee to independent review committee.
Changes to the protocol
Administrative and Formatting changes are present throughout the document.
Glossary of Terms:
Update definition of relapse to include 5% blasts in peripheral blood or bone marrow
Section 2.2, 2.4 and 4.1:
Deleted “Comparative” or “Comparator” language throughout the document. This trial is not 
a comparative trial.
Section 2.3 and 4.1:
Replaced “Stud y Steering Committee” with “Independent Review Committee”
Section 3: Objective and End Points
Table 3 -1:
Section 5.1: Patient Population
Addition of “Enrollment criteria will be evaluated at both Visit 1 (screening) and Visit 2 
(C1D1), prior to randomization.”
Section 5.2: Inclusion Criteria:
Addition to inclusion criteria 4: “Peripheral blood”
Addition to inclusion criteria 7:
“Patients must have received a myeloablative conditioni ng regimen prior to HSCT. The 
following regimens are considered to be myeloablative. Alternative myeloablative regimens 
must be approved b y [COMPANY_001] prior to enrollment.”
 

[COMPANY_001] Confidential Page 15
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
“Busulfan dosing based on individual PK parameters is allowed as long as myeloablative 
dosing is used (e.g ., target AUC at least 4000 µM x min for 4 day s).
Section 5.3: Exclusion Criteria
Addition to Exclusion criteria 3:
“haploidentical or cord blood”
Addition to Exclusion criteria 4:
“uncontrolled diabetes and chronic active pancreatitis”
Deletion from Exclusion criteria 6 and added as separate criteria:
“Patients with any pulmonary  infiltrate including those suspected to be of infectious origin 
(unless resolves to ≤ Grade 1 within screening timeframe) ”
Addition to Exclusion c riteria 8:
“(For GVHD proph ylaxis refer to Section [IP_ADDRESS])”
Addition to Exclusion criteria 9:
“GVHD related biops y”
Updated Exclusion criteria 15:
Changed 3 to “5” months for male contraception.
Section 6.3.1: Dose modification and dose delay
Updated thislanguage “. It is anticipated that dose interruption will be common during the 
early post-transplant period and the intent is to allow time to assess whether events are due to 
midostaurin, GVHD or other causes and to allow patients to remain on study .”
Addition to Table 6
-2:
Pulm onary Infiltrates
Grade 3 or 4 Pulm onary infiltrate interruption of midostaurin for the 
remainder of the cycle until the infiltrate resolves to ≤ 
grade.
Deletion from other adverse events (Non -Hematologic): “if the toxicities occurred in the first 
2 months of treatment. Patients who tolerate this resumption of 50mg b.i.d dose may remain 
on this dose.”
Addition to table notes: “Investigator discrection to continue study  drug (midostaurin) may  be 
used for the following if it is felt that the AE is not study  drug related:
Cytopenias, AST/ALT elevation, Nausea or Vomiting. All of other AEs require dose 
modification per Table 6 -2.”
Section 6.4: Concomitant medications
Addition of “ Sorafenib” to prohibited drugs
Section [IP_ADDRESS]:
Title updated to “Concomitant medications with potential for CYP3A4 interactions”
 

[COMPANY_001] Confidential Page 16
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Deleted this language “Midostaurin is primarily metabolized by [CONTACT_097]3A4 enzy mes. Drugs 
which are substrates of CYP3A4 only (not inhibitors nor inducers) are not likely  to interact 
with midostaurin. The recommendation is to avoid the co -administration of a strong CYP3A4 
inhibitor or a strong or moderate CYP3A4 inducer with midostaurin.”
Section [IP_ADDRESS].1 and [IP_ADDRESS].3: Updated with study codes
Section [IP_ADDRESS].2:
Deleted “str ong” from title
Addition of “ Moderate CYP3A4 inhibitors: Caution should be exercised for patients receiving 
moderate CYP450 3A4 inhibitors. A list of moderate CYP450 3A4 can be found on:
http://medicine.iupui.edu/clinpharm/ddis/main- table/ ”
Section [IP_ADDRESS].4:
Deleted this information from other section and updated here
Section 6.6.1: Study drug packaging and labelling:
Addition of “ The drug should be stored in the blister pack until use and no further preparation 
of the study  drug is needed.”
Deleted due to duplication of information already  captured in subcategories Section 6.6
“Midostaurin will be provided as soft gelatin capsules to be taken orally . No further 
preparation of the study  drug is needed. Two capsules of midostaurin 25 mg should be taken 
orally twice a day and a sufficient amount of study  drug has to be dispensed to the patient at 
each visit.
Important :The storage conditions for study  drug have to be maintained as described on the 
medication label. ”
Section 6.6.2: Drug supply and storage
Addit ion to storage “ Do not store above 25° C”
Section 6.6.4: Disposal and destruction
Addition to disposal language “Patients must return any remaining capsules should to the 
clinical site for proper disposal. Contact [CONTACT_230755].”
Section 7.1: Study flow and visit schedule
Changes in Table [ADDRESS_277800] be drawn within 14 days before randomization instead of 21 days before 
randomization.
Addition of physical exam to be performed in cy cle1 Day  3 visit.
Deletion of optional gene expression sample to be taken at Day 30 - 100, C6D1 and C12D1
Updated language to “Study  Drug dispensation and review”
 

[COMPANY_001] Confidential Page 17
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Addition of “archived stored frozen mononuclear cells/DNA” from Historical samples.
Section 7.1.1: Screening
Updated Gene Expression language to 
Patients are only required to complete failed assessments as long as the patient is re-screened 
within [ADDRESS_277801] met eligibility  by [CONTACT_2006]  60
Section [IP_ADDRESS]: Information to be collected on screening failures
Updated language to “. All data for screen failures are entered into the IWRS system, 
including the reason for not being started on treatment”
Addition of “All screen failure data from the IWRS will be exported to a SAS dataset for final 
data review and archiving.”
Section [IP_ADDRESS]: Study Evaluation Completion (SEC)
Updated language from Disease progression to “Relapse”
Table 7 -4: Bone marrow collection plan
Updated language from Historical to “Results from initial diagnosis required for eligibility ”
Section [IP_ADDRESS]: Laboratory evaluations
Updated screening laboratory  test should be drawn with 14 days of study  entry instead of 7 
days
Table 7 -6: Local clinical laboratory parameters collection plan
Serum “L ipase and Amy lase” to be included in labs (chemistry ) to be drawn at regular visits
Addition of “All efforts should be made to collect the labs prior to dosing. Fasting is not 
required for them.”
Section 7.2.2. 5.1: Pregnancy and assessments of fertility
Updated child bearing potential language here are per exclusion criteria no. 14
Section [IP_ADDRESS]: Radiological examinations
Addition of “If a CXR was done within 14 days of screening assessments then it does not 
need to be repeated”
Section [IP_ADDRESS]: Central determination of FLT3 ITD status
Deletion of “Both results will be used in the analy sis. If the results are discordant, 
the results 
will be summarized” and updated in Section 10.5.4
 

[COMPANY_001] Confidential Page 18
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
 

[COMPANY_001] Confidential Page 19
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Section 8.4: Pregnancy prevention requirements
Addition of this new title here and added a link for these requirements
Section 8.8: Independent Review committee
Updated independent review committee members selection criteria to those transplant expert 
physicians who are not participating in the trial
Section 10.5.4: Biomarkers
Addition of “The FLT3 results from the centralized assay  using archived material will be 
compared to the local result, and differences will be described
In addition, the clinical outcome of RFS and DFS based on the FLT3 ITD result from the 
centralized assay  compared to the local F LT3 ITD status will also be described.”
Section 10.8: Sample size calculation
Addition of sample size calculation assumption
“The sample size for the trial was chosen 30 patients per treatment arm to get separate 
estimates of the primary  endpoint relapse free survival”
“If the two arms were compared, the following gives the power that could be achieved under 
2 scenarios of relapse rate with 30 patients per treatment arm.
Scenario 1: Assuming a 30% relapse rate in the SOC arm
Scenario 2: Assuming a 50% reduction with midostaurin (experimental arm)
i.e., 15% relapse rate in the experimental arm, a sample size of [ADDRESS_277802] the reduction with 71% power. This calculation is based on 
one-sided type I error rate 
of 20%. The power would be 81% if we assume relapse rate to be even lower at 12% keepi[INVESTIGATOR_230726].”
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes d escribed in this amended protocol.
 

[COMPANY_001] Confidential Page 20
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Protocol summary :
Protocol number CPKC412AUS23
Title A Phase II, randomized trial of standard of care, with or without 
midostaurin to prevent relapse following allogeneic hematopoietic stem 
cell transplantation in patients with FLT3 -ITD mutated Acute Myeloid 
Leukemia
Brief title Study to prevent relapse in FLT3 -ITD mutated AML patients treated with 
standard of care (SOC) with or without midostaurin (PKC412) post 
allogeneic hematopoietic stem cell transplant.
Spons or and Clinical 
Phase[COMPANY_001]
Investigation type Drug
Study type Interventional
Purpose and rationale To determine if the addition of midostaurin (PKC412) to Standard of Care 
(SOC) therapy reduces relapse in FLT3 -ITD mutated AML patients 
receiving allogeneic hematopoietic stem cell transplantation.
Primary Objective(s) To determine if the addition of midostaurin to standard of care (SOC) 
therapy reduces relapse after at least [ADDRESS_277803] complete 
remission (CR1)
Secondary Objectives To evaluate disease free survival (DFS)
To evaluate relapse free survival (RFS) all along the study
To evaluate non -relapse mortality (NRM)
To evaluate overall survival (OS)
To evaluate safet y and tolerability of midostaurin in patients FLT3- ITD 
AML in the post -transplant setting
To evaluate pharmacokinetics (PK) of midostaurin
To assess FLT3 -ITD mutation status centrally in archived material 
from diagnosis (if available) including the mutant: wild type ratio
Study design This is a randomized, open label Phase II study  to investigate the efficacy  
and safety of 50mg twice daily midostaurin in patients with FLT3 ITD 
mutated AML after HSCT.
Population [ADDRESS_277804] of Care +/ -Midostaurin; (30 patients 
per treatment arm)
Male and Female patient s, aged 18 to ≤ 70 years old, FLT3 -ITD mutated 
AML patients receiving allogeneic hematopoietic stem cell transplantation
 

[COMPANY_001] Confidential Page 21
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Inclusion criteria Patients must be between 18 and 70 years of age
Patients must have an ECOG Performance Status of ≤ 2
Patients must have a documented Unequivocal diagnosis of AML 
according to W HO 2008 classification (>20% blasts in the bone 
marrow and/or peripheral blood), excluding M3 (acute prom yelocytic 
leukemia).
Patients must have a documented FLT3 ITD mutation, determined by 
[CONTACT_230756] (historical tissue will be requested for 
central analy sis confirmation)
Patients who have undergone allogeneic HSCT in CR1 from a 
matched related or matched unrelated donor. All of the following 
criteria must also be met:
HLA t ypi[INVESTIGATOR_230727] 8/8 or 7/8 allele HLA matched donor 
(at A,B,C, DRB1) Single allelic mismatch allowed
Patients who received one of the following conditioning regimens 
Alternative regimens must be approved by [CONTACT_230757]:
Busulfa n*/Fludarabine (Bu/Flu)
Busulfan (16 mg/kg PO or 12.8 mg/kg IV)
Fludarabine (120 -180 mg/m2)
Fludarabine / Melphalan (Flu/Mel)
Fludarabine (120 -180 mg/m2)
Melphalan ( ≤ 150 mg/m2)
Busulfan*/Cyclophosphamide (Bu/Cy)
Busulfan (16 mg/kg PO or 12.8 mg/kg IV)
Cyclophosphamide (120 mg/kg)
Cyclophosphamide/Total Body Irradiation (Cy/TBI)
Cyclophosphamide (120 mg/kg)
TBI (1200 -1420 cGy)
Note: Busulfan dosing based on individual PK parameters is 
allowed as long as m yeloablative dosing is used (e.g., target AUC 
at least 4000µM x min for 4 day s)
Recovery of counts by [CONTACT_4475] [ADDRESS_277805] (first dose of midostaurin to start no earlier than [ADDRESS_277806]); ANC >1000µL, platelets ≥20,000 without platelet 
transfusion
Patients must have the following laboratory values:
AST and ALT ≤ 3 x Upper Limit of Normal (ULN)
Serum Bilirubin ≤ [ADDRESS_277807]
Serum Creatinine ≤ 2.[ADDRESS_277808]
Exclusion criteria Patients whom have failed prior attempts at allogeneic HSCT
Patients who have received an autologous transplant, haploidentical or 
cord blood.
Patients with Acute GVHD Grade III- IV
Patients with any other known concurrent severe/and or uncontrolled 
medical condition (expect carcinoma in -situ), which could compromise 
participation in the study ( e.g. uncontrolled infection, uncontrolled 
diabetes, chronic active pancreatitis)
Patients with a known confirmed diagnosis of HIV infection or active 
viral hepatitis.
 

[COMPANY_001] Confidential Page 22
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Impaired cardiac function including any of the following:
-Screening ECG with a QTc > 450 msec. If QTc > 450 and electrolytes are 
not within normal ranges, electrolytes should be corrected and then the 
patient rescreened for QTc.
-Patients with congenital long QT sy ndrome
-History or presence of sustained ventricular tachycardia
-Any history o f ventricular fibrillation or torsades de pointes
-Bradycardia defined as HR. < 50 bpm
-Right bundle branch block + left anterior hemiblock (bifascicular block)
-Patients with m yocardial infarction or unstable angina < 6 months prior to 
starting study
-Congestive Heart Failure NY Heart Association class III or IV
-Patients with an ejection fraction < 45% assessed by [CONTACT_230758] ---ECHO 
within 21 days prior to starting study c ycle 1 (of midostaurin or control 
group)
Patients with any pulmonary infiltrate includi ng those suspected to be 
of infectious origin (unless resolves to ≤ Grade 1 within screening 
timefram e)
Antineoplastic chemotherapy or radiotherapy, within 21 days prior to 
study c ycle 1.
Patients who have had any surgical procedure, excluding central 
veno us catheter placement or other minor procedures (e.g. skin 
biopsy) within 14 days prior to study c ycle 1.
Patient requires treatment with strong CYP3A4 inhibitors or moderate 
or strong CYP3A4 inducers other than those required for GVH or 
infection prophyla xis or treatment
Known sensitivity to study drug(s) or class of study drug(s)
Participation in a prior investigational study within [ADDRESS_277809], 
whichever is longer
Pregnant or nursing ( lactating) women, or women of child- bearing 
potential, must use highly effective methods of contraception during 
dosing and for 30 day s after treatment period
Sexually active males unless they use a condom during intercourse 
while taking drug and for 5 mon ths after stoppi[INVESTIGATOR_230728]. They should not father a child in this period. A condom is 
required to be used also by [CONTACT_230759].
Not able to understand and to comply with study i nstructions and 
requirements
Investigational and 
reference therapyMidostaurin (PKC412)
Efficacy assessments Relapse Free Survival (RFS),
Disease Free Survival (DFS),
Overall Survival (OS)
 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Safety assessments Adverse Events (AEs)
Physical examination
Vital Signs and weight
Performance status
Laboratory evaluations
ECGs
Non-Relapse Mortality (NRM)
Other assessments Pharmacokinetics (PK) of midostaurin
FLT3 -ITD mutation status in archived material from diagnosis



Data analysis The primary  efficacy  criterion is the relapse free survival (RFS). The 
primary  objective is related to the Kaplan- Meier estimate at 18 months.
Efficacy  variables will be analyzed using Kaplan -Meier and Cox methods. 
For more details refer to Section 10.4.2 .
Safety endpoints will be assessed using descriptive statistics.
Key words acute m yeloid leukemia, FLT3 -ITD; m idostaurin; PKC412; allogeneic stem 
cell transplant; hematopoietic stem cell transplantation (HSCT)
 

[COMPANY_001] Confidential Page 24
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
1 Background
1.1 Overview of acute my eloid leukemia, epi[INVESTIGATOR_230729] (AML) is a malignant disord er of immature hematopoietic cells. It is 
characterized by [CONTACT_230760]. AML represents about 30% of the forms of adult leukemia 
and the incidence is estimated at 13,000 new cases per year in the U.S. and incidence 
increases with age. The American Cancer Society  also estimates the number of deaths due to 
AML  as 9,000 per y ear. ( American Cancer Society 2011 )
The diagnost ic workup of acute leukemia is multifaceted and may include bone marrow 
biopsy , flow cytometry , cytogenetics, and gene mutation analysis. The 2008 WHO 
classification categorizes myeloid leukemia into numerous subty pes and prognostic groups. 
The presence ofabnormal cytogenetics, or the presence of leukemia -associated gene 
mutations (FLT3, NPM1, CEPBA) are important prognostic indicators. (Estey  2010) 
Treatment approaches in AML vary for patients with APL (M3) but have remained relativel y 
unchanged for the past three decades for all other types of AML.
Combination chemotherapy regimens commonly used in treatment of non-APL  AML have 
typi[INVESTIGATOR_1306] y included induction with an anthracy cline and nucleoside analog. Complete remission 
(CR) rates of 65-90% in younger AML patients can be observed with daunorubicin or 
idarubicin given in conjunction with cytarabine for one to two cycles. (Ravandi 2007) 
Recently , higher doses of daunorubicin have shown better results in younger AML  patients 
although this benefit did 
not extend to the FLT3 ITD patients ( Fernandez 2009). 
Consolidation therapy  typi[INVESTIGATOR_230730] y includes three to four cycles of post-remission therapy . 
(Estey  2010)
Despi[INVESTIGATOR_151153], the majority  of adults with AML  will relapse withi n 
3 years with 
only 40-45% of younger patients achieving cure. (Burnett 2011) There are subsets of AML 
patients with very poor outcomes, including intermediate or poor risk by [CONTACT_230761]. In such cases, approaches including 
stem cell transplantation (HSCT) are 
recommended in CR1. ( NCCN Guidelines v1.2012 , Estey  2010 )
1.1.1 FMS -like tyrosine kinase 3 mutations
The FMS -like tyrosine kinase 3 (FLT3) belongs to the group of class III receptor tyrosine 
kinases. It belongs to a family  of important signaling receptors that include c
-KIT, c-FMS, 
and PDGFR. FLT3 is a growth factor receptor involved in hematopoietic cell growth and 
differentiation. FLT3 receptor and its ligand (FL) also play an important role in survival and 
self-renewal of early hematopoietic progenitors, monocy tic precursors and in lymphoid 
development. Activation of FLT3 results in receptor auto- phosphory lation leading to 
downstream signaling of the RAS/MAPK, JAK/STAT5, and PI3K/AKT pathway s. In normal 
bone marrow (BM), FLT3 is expressed on progenitor cells and regulates stem cell 
proliferation. As hematopoietic progenitor cells differentiate and mature, FLT3 expression is 
normally  lost.
 

[COMPANY_001] Confidential Page 25
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
In AML, signaling of FLT3 pathway  is often activated and leads to malignant blast cell 
proliferation, in part due to over expression of FLT3 receptor in leukemia cells. However, a 
major research advance was the identification of mutations occurring in the FLT3 gene in 
AML  patients. It is the most common somatic mutation identified in AML, with an incidence 
of about 25% (Kindler 2010, Kottaridis 2001). Two major types of FLT3 gene mutation have 
been identified: 1) internal tandem duplication (ITD) and 2) tyrosine kinase domain (TKD) 
point mutations (PM) and ITDs make up a majority  of FLT3 mutations in newly  diagnosed 
patients 
(Thiede 2002). These duplications are the result of 3 to > 400 base pairs inserted into 
the receptor in-frame (Schnittger 
2002). The ITDs promote ligand -independent FLT3 receptor 
dimerization and signal activation, culminating in cellular proliferation (Kiyoi 1998, 
Hayakawa 2000
).
The presence of FLT3 -ITDs has been found in certain studies to be the strongest predictor of 
patient outcome (Kottaridis 2001, Kiyoi 1999). AML  patients harboring FLT3 ITD mutations 
are characterized by [CONTACT_230762] (Frohling 2002, Thiede 2002 ). FLT3 ITD has been 
reported consistentl y as an unfavorable prognostic marker for relapse -free (RFS) and overall 
survival (OS) (Kottaridis 2001, Frohling 2002, Thiede 2002, Gale 2008). In a  s tudy of 854 
AML  patients, an ITD was present in 27% of the patients. Although presence of FLT3 
mutation did not impact CR rate, long term clinical outcomes varied based on the presence of 
FLT3 ITD. The relapse rate at 5 years was 64% in patients with the mutation versus 44% in 
those witho ut. Disease free survival at 5 years was 30% compared to 46% in patients without 
a mutation and overall survival of 32% compared to 44% of patients without the mutation. 
(Kottaridis 2001)
Furthermore, additional factors of the FLT3 ITD mutation may impact outcome, including 
size of the base pair insertion, higher allelic ratio (mutant: wild-type FLT3) and insertion site 
(Stirewalt 
2006, Thiede 2002, Kayser 2009 ) As details of FLT3 ITD mutations continue to be 
evaluated, it remains clear that AML with a FLT3 ITD mutation results in higher relapse,
shorter DFS and shorter OS which has led to an increased focus on HS CT in CR1 in this 
group.
1.1.[ADDRESS_277810] 
remission treatment options include intensive conventional chemotherapy (often high dose 
cytarabine), prolonged maintenance treatment, or intensive therap y followed by  [CONTACT_230763] (HSCT). Patients with high-risk AML are 
typi[INVESTIGATOR_1306] y evaluated for HSCT early  as the chance of long-term cure with chemotherap y alone 
is low. Allogeneic HSCT is a highly  effective treatment for AML , with improved progression 
free survival (PFS) and OS for patients with intermediate and high-risk disease. 
(Yanada 2005, Estey  2011 )
In the subset of patients with FLT3 ITD mutations whom achieve complete remission, 
outcomes of HSCT have so far only been reported 
in three large retrospective analyses.The 
MRC group compared outcomes in FLT3 ITD+ and FLT3 ITD-patients (Gale 2005 ) This 
intent to treat analysis (donor versus no donor) failed to show a statistically  significant 
 

[COMPANY_001] Confidential Page 26
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
difference between HSCT and no HSCT in FLT3 ITD patients; however the small sample size 
of 35 FLT3 ITD allograft patients limits the power in the analysis (Gale 2005, Gale 2007 ). 
The observed OS in the allograft patients at 5 years was 58% and 44% in the FLT3 ITD-and 
ITD+ groups, respectively . The rate of relapse over 5 years was 31% in FLT3 ITD+ and 25% 
in FLT3 ITD -patients whom were allograft recipi[INVESTIGATOR_840].
An AML SG analysis also compared outcomes for patients with FLT3 ITD versus FLT3 wild 
type (WT) in groups given post-remission chemotherap y, autologous HSCT or allogeneic 
HSCT. (Bornhauser 2007 ) The 376 younger, interme diate risk 
patients included 176 patients 
with FLT3 ITD. Overall, there were 103 matched sibling allogeneic transplants, 141 
autologous transplants and 132 chemotherap y recipi[INVESTIGATOR_230731]. Kaplan Meier 
analyses show that transplant increased OS in the FLT3 ITD+ patients to similar levels as 
FLT3 WT patients who underwent allogeneic or autologous transplant (approximate median 
OS 72 months for allogeneic and 36 months for autologous). The group of FLT3 ITD patients 
whom received chemotherapy  had amuch shorter OS than FLT3 WT. While this study  shows 
benefit with HSCT in FLT3 ITD, the OS is double that of other literature reports in FLT3 WT 
AML . Discussions amongst researchers point to likely  exclusion of early  TRM and/or 
censoring the early relapse events in FLT3 ITD which could introduce bias and magnify  the 
difference between the arms (Schlenk 2008, Bornhauser 2007, Meshinchi 2006). Following 
allogeneic HSCT, relapse occurred in about 35% of patients in the FLT3 ITD group (N=40) 
which was much higher than in the FLT3 wild type (N=60) patients at a median follow -
up of 
53 months. ( Bornhauser 2007)
 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Figure 1-[ADDRESS_277811] remission 
therapy
Probability of ov erall survival and relapse according to postremission therapy .After a median 
follow -up of 53 months for surviving patients, the probability of overall survival and relapse (from 
remission) are shown for patients having received either chemotherapy (n = 132), autologous 
transplant (n = 141), or allogeneic transplant (n = 103) as postremission therapy. Tx indicates 
transplantation. ( Bornhauser 2007 )
These findings were corroborated by [CONTACT_230764]. Of [ADDRESS_277812] with myeloablative 
conditioning, FLT3 ITD was observed in 120 (58%) patients. This is the largest group of FLT 
ITD patients undergoing allogeneic transplant and was the most clearl y defined patient group 
of the three retrospective analyses. The incidence of relapse at two years was higher in the 
FLT3 ITD positive group at a rate of 30% compared to 16% in the negative group. Disease 
free survival was also negativel y impacted b y FLT3 positive status (DFS at 2 y ears of 58% vs. 
71% in FLT3 ITD negative) ( Brunet 2012). Despi[INVESTIGATOR_230732], patients with 
FLT3 ITD relapsed at a much higher rate than patients without the mutation. Most relapses in 
the FLT3 ITD group occurred by [ADDRESS_277813]. Despi[INVESTIGATOR_230733], they report a similarl y high rate of relapse of 30
-35% in patients with 
FLT3 ITD undergoing allogeneic HSCT.
 

[COMPANY_001] Confidential Page 28
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Figure 1-[ADDRESS_277814] CR for patients with AML and normal cy togenetics 
according to the presence (dashed line) or absence (solid line) of ITD of FLT3 gene. (A) Estimated 
probability of 2 years of cumulative incidence of relapse; (B) leukemia -free survival after 
transplantation at 2 years. ( Brunet 2012 )
Due to the poor prognosis conferred with a FLT3 ITD mutation, many  centers are prioritizing 
allogeneic HSCT for these patient s who remain at high risk for relapse. (Levis 2011 , 
Van denBrink 2010) New treatments which could improve relapse rates after HSCT would be 
a signi ficant benefit. Clinical trials are now launching to understand whether maintenance 
therap y targeting FLT3 ITD shortl y after allogeneic transplantation can delay  or prevent 
relapse in this high risk subset of AML patients ( Metzelder 2009, Sora 2011 , Levis 2010 ).
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of m idostaurin
Midostaurin is an inhibitor of several protein kinase C (PKC) isoforms, of the tyrosine kinase 
of the vascular endothelial growth factor receptor (VEGFR) and most importantly  of the class 
III tyrosine protein kinases FLT3 (fms-like tyrosine kinase-3) and KIT which are involved in 
hematopoiesis and play  a key  role in certain hematopoietic disorders. Midostaurin binds to the 
catal ytic domain of these kinases and inhibits the signaling of the respective growth factors in 
cells and results in growth arrest. The anti-proliferative effects of midostaurin were easily 
detectable in FLT3 -ITD, FLT3 -TKD and FLT3 WT cells (Weisberg 2002 , Barry  2007). 
Midostaurin has also been found to revert the P -glycoprotein (Pgp) mediated MDR (multidrug 
resistance) phenot ype b y inhibiting the function of Pgp ( Utz 1998 ).
Midostaurin is currentl y in Phase II/Phase II I clinical development including:
 

[COMPANY_001] Confidential Page 29
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Two phase II single arm single agent studies in patients with aggressive systemic 
mastocy tosis / Mast Cell Leukemia
One phase III randomized, double -blind study  (CALGB [ZIP_CODE]; RATIFY) in patients with 
FLT3 -mutated AML.
[IP_ADDRESS] Clinical experience
[IP_ADDRESS].1 Pharmacokinetic and pharmacodynamic data
The clinical pharmacology  of midostaurin has been extensively  studied in healthy  volunteers 
as well aspatients with AML  and diabetes mellitus (Yin 2008; Stone 2012 ). Midostaurin is 
rapi[INVESTIGATOR_230734] 1-[ADDRESS_277815] 3-8 days.Thereafter, the PK becomes non-linear with an apparent 
large increase in CL/F. This relatively  high apparent oral clearance necessitates a high dosing 
rate (e.g. bid administration) to maintain target drug levels in the long term. Midostaurin 
concentrations reach steady -state after 28 days of daily  dosing. (Yin 2008 ) In vitro studies 
have shown that midostaurin, CGP62221, and CGP52421 inhibit mutant FLT3 at low 
nanomolar concentrations, with IC50s of 10-36 nM, 26 nM and 584nM, respectivel y. 
(Manley 2003; Stone 2012 )
Midostaurin is predominantly  metabolized by [CONTACT_097]3A4 iso-enzymes to form two major, 
pharmacologically  active metabolites which may contribute to in vivo activity : CGP62221 
(half -life ~ 30 hours, comparable to midostaurin’s half-life of ~25 hours) and CGP52421 
(half -life of ~28 days). Phase I studies in healthy  volunteers evaluated the effects of a strong 
CYP3A4 inhibitor (ketoconazole) anda strong CYP3A4 inducer (rifampin) on concentrations 
of midostaurin and its metabolites and the effect of midostaurin on midazolam (a sensitive 
CYP3A4 substrate). Concomitant administration with strong CYP3A4 inhibitors or inducers 
significantl y alters midostaurin concentrations. Midostaurin does not cause a drug-drug 
interaction with CYP3A4 substrates.
For additional pharmacokinetic information, please refer to the Investigators Brochure.
[IP_ADDRESS].2 Overview of efficacy with midostaurin
Midostaurin has demonstrated activity  in patients with relapsed or refractory 
AML /myelodysplastic syndrome (MDS) in Studies CPKC412A 2104 (2104) and 
CPKC412A 2104E1 (2104E1) . In Study  2104E1, the rate of BR (blast reduction) for the 
efficacy  population (n=92) was 71% in FLT3 -mutant patients and 42% in FLT3 -WT patients. 
One partial response (PR) occurred in a FLT3 -mutant patient on the 100 mg b.i.d. dose 
regimen. Both doses levels evaluated in this trial (50 mg b.i.d., and 100 mg b.i.d.) were well 
tolerated; the toxicity  profiles and response rates were similar for the two doses of 
midostaurin. The results suggest that midostaurin has hematologic activity  in both FLT3 -
mutant and wild-type patients. The degree of clinical activity  observed supports further 
studies in earlier stage disease and that combine midostaurin with other agents 
such as 
chemotherap y especially  in FLT3 -mutant AML ( Fischer et al 2010).
 

[COMPANY_001] Confidential Page 30
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
Preliminary  data from the phase Ib,CPKC412A 2106 (2106), study of midostaurin in 
combination with standard daunorubicin and cytarabine therapy  in patients with newly  
diagnosed AML patients indicate that midostaurin at 50 mg p.o. b.i.d. can be given with 
tolerable side effects in this patient population ( Stone 2012 ). Efficacy  data for the 50 mg b.i.d. 
population was presented at the American Society  of Hematology  (ASH) in 2009. The 
investigator assessment of Complete response (CR) occurred in 32/40 (80%) of all patients 
(20/27 [74%] of FLT3–WT patients, 12/13 [92%] of FLT3 –mutant patients). One and 2 year 
overall survival (OS) for the patients with FLT3 –mutant AML was 85% and 62%, 
respectivel y, and was comparable to that of the FLT3–WT subgroup (81% and 59%, 
respectivel y). This data was based on small numbers and not stratified for type of FLT3 
mutation (TKD, ITD, or allelic ratio) (Stone 2009). This study  supported the ongoing double 
blind, placebo controlled, phase III study , CPKC412A2301 (CAL GB [ZIP_CODE], Ratify ), in newl y 
diagnosed FLT3 mutated AML . Enrollment in that trial is complete (N=717) and awaiting the 
Overall Survi val (OS) events required for final analy sis
.
In addition to the AML programs described above, an ongoing single arm, phase II study , 
CPKC412D2201 (2201) in aggressive systemic mastocytosis / mast cell leukemia has 
completed enrollment with stage I (N=40) a nd extension (N=40) to determine the efficacy  and 
safet y of 100 mg twice daily  oral midostaurin as a single agent. The Overall Response Rate, 
per Valent criteria, for stage I is 60% (24/40 eligible patients) including a major response rate 
of 52.5%. ( Gotlib 2012 )
[IP_ADDRESS].[ADDRESS_277816] received midostaurin including ~650 patients with 
AML  / MDS. In AML patients, doses of up to [ADDRESS_277817] been given, but the 50 mg 
twice daily dose is recommended based upon reaching the IC50 and showing acceptable 
tolerability . Safet y data in AML  are based upon three studies: monotherapy  in FLT3 mutated 
patients (2104 Core; N=20), monotherap y in relapsed AML or ineligible for chemotherap y 
(2104E1; N=95) and front -line combination therapy  with daunorubicin and cytarabine (2106; 
N=69). (Stone 2005, Fische r 2010, Stone 2012 ). Data from the maintenance phase of the 
Phase III (2301, CALGB [ZIP_CODE] Ratify )study  would also be very  informative but the ongoing 
trial remains blinded at this time. Single agent saf ety data from 2104E1 will be discussed.
In study  2104E1, patients were randomized to receive midostaurin at doses of 50 mg b.i.d. or 
100 mg b.i.d. Of the patients enrolled, 73% were relapsed/refractory  and 61% were greater 
than [ADDRESS_277818] frequent events were grades 1 or 2 nausea 
(61%; Grade 3 was 1%), vomiting (49%; Grade 3 was 1%), diarrhea (44%; Grade 3 or 4 was 
5%), fatigue (38%; Grade 3 was 3%),pyrexia (35%; Grade 3 was 7%) and dyspnea (29%; 
Grade 3 or 4 9%). The most commonly  reported grade 3 / 4 AEs 
were febrile neutropenia 
(21%), thrombocy topenia (19%), neutropenia (12%), anemia (13%) and pneumonia (12%). 
[Inv Brochure ed 16, Table 6-20] The decreases observed in the hematology  parameters were 
as expected for 
this patient population. Only  one patient discontinued treatment due to a 
hematologic abnormality (grade 3 febrile neutropenia). The majorit y of new or worsened 
biochemistry  abnormalities were of CTC grade 1-2. There were grade 3 or 4 abnormalities in 
 

[COMPANY_001] Confidential Page 31
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
AST/AL T in 13% patients (2 were Grade 4, both receiving 100 mg b.i.d.), amylase 7% and 
albumi n 
5%. The full table of newly  occurring or worsening hematology  and chemistry 
abnormalities is shown in the I nvestigators Brochure Version 16. [Tables 6- 21 and 6-22]
SAEs were reported for 71 (75%) patients and most commonly  included: febrile neutropenia 
(20 patients), pneumonia (17 patients), pyrexia (13 patients), dyspnea (8 patients), 
thrombocy topenia (7 patients) and anemia (6 patients). The incidence of SAEs was similar for 
both dose groups. SAEs were mostl y considered to be due to disease progression. Eighteen 
(19%) patients had SAEs that were considered related to study  drug, with grade 3/[ADDRESS_277819] frequently  reported .
In 2011, a pooled safety  analysis was performed using data available from 14 solid tumor or 
AML /MDS studies. Trials included combinations with 5-FU, paclitaxel, gemcitabine, 
carboplatin, cisplatin, daunorubicin, and cytarabine. The pooled analysis included 542 
subjects (213 with AML/MDS) and the most common drug related toxicities (> 20%) in these 
phase I/II trials were nausea, vomiting and diarrhea, general disorders / administration site, 
nervous system disorders (including 
headache, dizziness, syncope), metabolism and nutrition 
disorders, and decreased appetite. AEs occurring less frequently  (10-19%) included fatigue, 
headache, anemia, AST/AL T elevations, thrombocy topenia and constipation. (Investigators 
Brochure, ed 15 )In the pooled anal ysis, frequencies of cardiac events were consistent with the 
investigated populations.
A Phase I trial evaluated th e effect of midostaurin on the QTc interval in healthy  volunteers in 
a thorough QTc study . The mean maximum change from baseline (QTcF) for midostaurin 
compared with placebo demonstrated a lack of QTcF prolongation effects. (DelCorral 2012) 
This trial evaluated midostaurin and the short acting metabolite but could not investigate 
effects of the long-acting metabolite at stead y state. The long acting metabolite information 
cannot be attained from a health y volunteer study  thus will be provided from the CALGB 
[ZIP_CODE] (Ratify ) dataset.
Overall, AEs suspected to be related to midostaurin treatment were mostly  Grade [ADDRESS_277820] common in the early cycles of administra tion. In the ongoing ASM/MCL  studies, 
patients are tolerating the 100 mg twice daily  dose for up to 4 years; however, proph ylactic 
anti-emetics are given to all patients.
2 Rationale
2.1 Stud y rationale and purpose
Midostaurin is an oral agent that has been show nto inhibit FLT3 kinase in preclinical in vitro 
and in vivo studies, as well as clinically  in patients with both ITD and TKD FLT3 mutations 
(FLT3mut). Both directly  and indirectl y, midostaurin also potentl y inhibits multiple other 
 

[COMPANY_001] Confidential Page 32
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
molecular targets though t to be important for the pathogenesis of AML. These targets include 
VEGFR -1, a VEGF receptor; c-kit; H-and K-ras; as well as the multidrug resistant gene, 
MDR. Midostaurin, a staurosporine derivative, has been identified as an inhibitor of both 
mutated and wild type FLT3 kinase. Midostaurin potently  inhibits recombinant FLT3 kinase 
in an in vitro kinase assay , and inhibits tyrosine phosphory lation of mutant FLT3, both ITD 
mutants and D835Y point mutants in vitro. These data suggest that midostaurin direct ly 
blocks the kinase activity of mutant FLT3, thereby [CONTACT_230765]. 
Expression of a mutant FLT3 receptor (FLT3- ITD or the TKD D835Y) in vivo in murine 
marrow cells results in a lethal myeloproliferative syndrome which can be successfull y cured 
with the administration of midostaurin. ( Weisberg 2002 )
2.[ADDRESS_277821] of care, with or without 
midostaur in to prevent relapse following allogeneic hematopoietic stem cell transplantation 
(HSCT) in patients with FLT3 -ITD acute myeloid leukemia. The intent of this study  is to 
evaluate whether the addition of midostaurin to standard of care (SOC) following allogeneic 
HSCT improves Relapse Free Survival (RFS) in FLT3 -ITD AML patients in first complete 
remission (CR1). This trial will not be powered to detect a difference between the two arms. 
Powering of the trial is not feasible considering the rare nature of FLT3-ITD mutant AML 
receiving a HSCT. With a 22-25% FLT3 -ITD mutation rate and approximately  25% rate of 
HSCT, estimated from the ongoing Phase III study  (2301, CALGB [ZIP_CODE] Ratify ), more than 
[ADDRESS_277822] which can be used to design a larger trial. There are no published sets of 
prospective, FLT3 -ITD AML  outcomes after transplantation .
2.3 Rationale for dose and regimen selection
Patients receiving midostaurin on this trial will receive 50mg b.i.d for 28 consecutive days of 
each cy cle.
In adults, the maximum tolerated dose (MTD) of the single agent was 75 mg t.i.d. in relapsed 
AML . Preliminary  PK/PD analy sis from this study  showed that the plasma level of 
midostaurin seems to be well above the IC50 value for FLT3 ITD/D835 inhibition. 
(Stone 2005) In this study , it was also demonstrated that single agent treatment up to [ADDRESS_277823] 
activity .
In relapsed
/refractory  AML patients, average trough concentrations observed at the 50-and 
100-mg doses showed that steady -state levels of midostaurin and the metabolites reached the 
50% inhibitory  concentration. This supports a minimum dose of 50 mg twice daily  in 
FLT3 
mutated AML . (Fischer 2010). Currentl y the [ADDRESS_277824] tolerable dosing, the dose 
for patients receiving midostaurin on this trial will be 50mg b.i.d daily. For patients unable to 
 

[COMPANY_001] Confidential Page 33
Amended Protocol Version 0 2 (Clean ) Protocol No. CPKC412AUS23
tolerate the proposed dose, dose adjustments are outlined in Section 6.3. An Independent 
Review committee (IRC) will additionally  review safet y information after 10, 20, and [ADDRESS_277825] of Care (SOC) therapy  and half of these patients 
will be randomized to receive midostaurin in addition to this. Currently , SOC therapy  varies 
per treating institution in the post HSCT setting but includes anti-infect ive proph ylaxis and 
treatment and GVHD prophy laxis and treatment.
A placebo will not be used in this trial. While a placebo was considered, it can limit 
enrollment which is already  expected to be the largest challenge for the trial. In addition, the 
primar y endpoint of the trial is relapse and clinical relapse in patients with AML is not 
expected to be impacted by  [CONTACT_230766]. The frequency  of relapse assessments is the 
key component and is the same for both arms.
All SOC treatment while on study  must be captured for all patients on the Concomitant 
Medications / Significant Non- drug Therapi[INVESTIGATOR_144924].
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3
-1below.
 

[COMPANY_001] Confidential Page 34
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Table 3-[ADDRESS_277826] of care 
(SOC) therapy reduces relapse after at least [ADDRESS_277827] complete remission (CR1)Relapse Free Survival (RFS) is defined as the time from 
transplant to relapse or death due to the disease [ADDRESS_277828] transplant
Key secondary Refer to Section 10.5 .
To evaluate disease free survival (DFS) DFS is defined as the time from transplant to relapse or 
death from any cause
To evaluate relapse free survival (RFS) all along the study Relapse Free Survival (RFS) is defined as the time from 
transplant to relapse or death due to the disease
To evaluate non -relapse mortality (NRM) NRM is calculated from the date of transplant to date of 
patient death due to reasons other than 
relapse/progressive AML.
To evaluate overall survival (OS) OS is defined as the time from transplant to the date of 
death from any cause
To evaluate safety and tolerability of midostaurin in patients with 
FLT3 –ITD AML in the post -transplant settingSafety will be assessed by [CONTACT_941] C ommon Toxicity Criteria 
for Adverse Events (CTCAE) version 4.0. Incidence of 
adverse events (AEs), serious adverse events (SAEs), 
changes from baseline in clinically notable changes in 
vital signs and CTC grading for laborator y results 
(hematology, blood c hemistry, ECGs) will be reported.
To evaluate pharmacokinetics (PK) of midostaurin in the post -
transplantPK concentration -steady state levels
To assess FLT3 -ITD mutation status centrally in archived 
material from diagnosis, if availableFLT3 -ITD mutation status, including the mutant:wild type 
ratio
 

[COMPANY_001] Confidential Page 35
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Objective Endpoint Analysis
 

[COMPANY_001] Confidential Page 36
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
[ADDRESS_277829] of Care (SOC) treatment with or without (+/-) 
midostaurin in a 1:[ADDRESS_277830] will be eligible for randomization no later than 60 days after transplant 
(may  occur as early  as day [ADDRESS_277831] transplant), regardless of treatment assignment. Based on 
other tyrosine kinase inhibitor data, it is anticipated that starting midostaurin shortly  after 
transplant will offer the best chance to improve relapse rates. Most relapses after transplant in 
FLT3 -ITD patients occur by  [CONTACT_4475] 100 so an earlier treatment s tart (days 28 to 60) is targeted in 
this trial. Midostaurin will be given at a dose of 50mg twice daily continuously  in cycles of 4 
weeks (28 days) each for up to 12 cycles or disease relapse or withdrawal due to any cause, 
whichever occurs earlier.
Patient visits will occur monthly  for one year during the Treatment Phase (Cycles 1-12). 
Visits will continue in the Follow -up Phase thru [ADDRESS_277832] bone marrow aspi[INVESTIGATOR_230735] (between days [ADDRESS_277833]), at Cycle 6, at Cycle 12, at relapse or more frequentl y if clinically  indicated. All 
patients will begin treatment, regardless of treatment assignment, upon recovery  of counts as 
listed in the eligibility  criteria. Patients who do not meet recovery  eligibility  criteria by [CONTACT_4475] [ADDRESS_277834] 3 cycles or discontinued. A n independent review committee of 3 to 5 study 
investigators will review safet y information to include (but not limited to) adverse events, 
serious AEs, lab parameters, bone marrow results .
 

[COMPANY_001] Confidential Page 37
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Figure 4-1 Study  design
1Standar d of Car e (SOC), 2Relapse Free Survival (RFS), 3Disease Free Sur vival, 4Non Relapse 
Mortality, 5Over all Survival, 6Pharmacoki netics, 7End of TreatmentMidostau rin Group
SOC1+ Midostaurin
(50mg BID)
Control Group
SOC112 cyclesPrimary  :
•18 month RFS2
Secondary: 
•DFS3
•RFS
•NRM4
•OS5
•Safetyand Tolerability
•PK6
•FLT3 mutational statusAML Patients
FLT-ITD+ in CR1
Recovery Post-
HSCT 
(MUD /MRD)
Count  Recovery 
by D42 
Treatment  starts 
by D28-D60 
post SCTRandomize 
1:1 
n = 60Screening Treatment Follow up  Endpoints
Adverse Even t 
Reporting 
[ADDRESS_277835]  and/or 
until end of study
4.[ADDRESS_277836] withdrawn from the study . Prior to database lock, anadditional OS and 
RFS update will be requested from all living patients.
4.3 Early study  termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible and the same assessments should be performed 
as described in Section 7.1.3 for a prematurely  withdrawn patient. The investigator may be 
informed of additional procedures to be followed in order to ensure that adequate 
consideration is given to the protection of the patient’s interests. The investigator will be 
responsible for informing I RBs and/or ECs of the earl y termination of the trial.
5 Population
5.1 Patient population
Patients with acute my eloid leukemia (AML) must have documented FLT3 -ITD mutation and 
have undergone allogeneic HSCT in first complete remission (CR1) to be eligible to enter the 
study .
Sixty  (60) patients will be enrolled during the study . The investigator or his/her designee must 
ensure that all patients who meet the following inclusion/exclusion criteria are offered 
 

[COMPANY_001] Confidential Page 38
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
enrollment into the study. Enrollment criteria will be evaluated at both Visit 1 (screening) and 
Visit 2 (C1D1), prior to randomization.
Patients enrolled in this study  are not permitted to participate in additional parallel 
investigational drug or device studies. Patients who have completed the study  may not be re-
enrolled for a second course of treatment.
5.[ADDRESS_277837] to meet all of the following criteria:
Written informed 
consent must be obtained prior to any screening procedures. If consent 
cannot be expressed in writing, it must be formally  documented and witnessed, ideall y via an 
independent trusted witness.
1.Patients must be betwee n [ADDRESS_277838] an ECOG Performance Status of ≤ [ADDRESS_277839] a documented Unequivocal diagnosis of AML according to WHO 
2008 classification (>20% blasts in the bone marrow and/or peripheral blood ), excluding 
M3 (acute prom yelocy tic leukemia).
5.Patients must have a documented FLT3 ITD mutation, determined by  [CONTACT_230767]  (historical tissue will be requested for central anal ysis confirmation)
6.Patients who have undergone allogeneic HSCT in CR1 from a matched related or matched 
unrelated donor. All of the following criteria must also be met:
HLA ty pi[INVESTIGATOR_230727] 8/8 or 7/8 allele HLA matched donor (at A,B,C, 
DRB1) Single allelic mismatch allowed
7.Patients must have received one of the following conditioning regimen s prior to HSCT.
Alternative regimens must be approved by [CONTACT_230757] :
Busulfan */Fludarabine (Bu/Flu)
Busulfan (16 mg/kg PO or 12.8 mg/kg IV)
Fludarabine (120 -180 mg/m2)
Fludarabi ne / Melphalan (Flu/Mel)
Fludarabine (120 -180 mg/m2)
Melphalan ( ≤ 150 mg/m2)
Busulfan */Cyclophosphamide (Bu/Cy)
Busulfan (16 mg/kg PO or 12.8 mg/kg IV)
Cyclophosphamide (120 mg/kg)
Cyclophosphamide/Total Body Irradiation (Cy/TBI)
Cyclophosphamide (120 mg/kg)
TBI (1200 -1420 cGy )
*Note: Busulfan dosing based on individual PK parameters is allowed as long as 
myeloablative dosing is used (e.g., target AUC at least 4000µM x min for 4 day s)
8.Recovery  of counts by  [CONTACT_4475] [ADDRESS_277840] of Care +/ -midostaurin by  [CONTACT_4475] [ADDRESS_277841] (first dose of midostaurin to start no earlier than [ADDRESS_277842])
 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
ANC >1000 perµL, platelets ≥20,[ADDRESS_277843] the following laboratory  values:
AST and ALT ≤3 x Upper Limit of Normal (ULN)
Serum Bilirubin ≤[ADDRESS_277844]
Serum Creatinine ≤2.[ADDRESS_277845] not meet anyof the following criteria:
1. Patients whom have failed prior attempts at allogeneic HSCT
2.Patients who have received an autologous transplant ,haploidentical or cord blood.
3. Patients with Acute GVHD Grade III- IV
4.Patients with any  other known concurrent severe/and or uncontrolled medical condition 
(expect carcinoma in -situ), which could compromise participation in the study  (e.g. 
uncontrolled infection , uncontrolled diabetes, chronic active pancreatitis)
5.
Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
6.Impaired cardiac function including an y of the following:
Screening ECG with a QTc > 450 msec. If QTc > 450 and electrol ytes are not within 
normal ranges, electrol ytes should be corrected and then the patient rescreened for 
QTc.
Patients with congenital long QT s yndrome
History  or presence of sustained ventricular tach ycardia
Any history  of ventricular fibrillation or torsades de pointes
Brad ycardia defined as HR. < 50 bpm
Right bundle branch block + left anterior hemiblock (bifascicular block)
Patients with my ocardial infarction or unstable angina < 6 months prior to starting 
study
Congestive Heart Failure NY Heart Association class III or IV
Patients with an ejection fraction < 45% assessed by  [CONTACT_230768] 21 day s 
prior to starting stud y cycle 1 (of midostaurin or control group)
7.Patients with any pulmonary infiltrate including those su spected to be of infectious origin 
(unless resolves to ≤ Grade 1 within screening timeframe)
8.Antineoplastic chemotherap y or radiotherap y, within 21 days prior to study cycle 1 (For 
GVHD proph ylaxis refer to Section [IP_ADDRESS])
9.
Patients who have had any surgical procedure, excluding central venous catheter 
placement or other minor procedures (e.g. skin biopsy/GVHD related biopsy ) within 14 
days prior to study  cycle 1
10.Patient requires treatment with (a) stron g CYP3A4 inhibitor other than those required for 
GVH or infection proph ylaxis or treatment or (b) moderate or strong CYP3A4 inducer
regardless of proph ylaxis or treatment
11.Known sensitivity  to study  drug(s) or class of study  drug(s)
 

[COMPANY_001] Confidential Page 40
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
12.Participation in a prior investigational stud y within [ADDRESS_277846], whichever is longer.
13.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by a positive hCG 
laboratory  test within 48 hours of beginning study treatment.
14.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using highly effective methods of contraception 
during dosing and for 3 months after treatment completion. Highly  effective contraception 
methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I n
case of oophorectom y alone, only  when the reproductive status of the woman has 
been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study the vasectomized male partner should be the sole partner for that subject.
Combination of any  two of the following (a+b or a+c, or b+c):
a.Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that h ave comparable efficacy  (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception.
b.Placement of an intrauterine device (IUD) or intrauterine s ystem (IUS)
c.Barrier methods of contraception: Condom or Occlusive cap (diaphragm o r 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_277847] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate, history  of vasomotor sy mptoms).
15.Sexually  active males unless they  use a condom during intercours e while taking drug and 
for 5months after stoppi[INVESTIGATOR_230736]. They  should not father a child in this 
period. A condom is required to be used also b y vasectomized men in order to prevent 
delivery  of the drug via seminal fluid.
16.Not able to understand and to comply  with study  instructions and requirements
6 Treatment
6.1 Stud y treatment
Study  Treatment refers to the treatment assigned upon randomization;
Standard of Care (SOC) or
Standard of Care ( SOC )with midostaurin.
 

[COMPANY_001] Confidential Page 41
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Study drug refers to any [COMPANY_001] investigational drug(s) being used for an unapproved 
indication. For this study , the term “Study  drug” refers to midostaurin (PKC412) supplied in 
25 mg soft gelatin capsules which are packaged in blister packs.
6.1.1 Midostaurin dosing re gimen
Table 6-1 Dose and drug schedule
Study drug Pharmaceutical form and 
route of administrationDose Frequenc y and/or 
Regim en
Midostaurin (PKC412) 25mg Soft gelatin capsule; 
oral administration50mg
(2 x 25mg) capsules)Twice Daily
(28 day cycles)
The standard dose of midostaurin is listed in Table 6-1and should be followed unless patients 
meet criteria for dose modifications Section 6.3.
6.1.2 Treatment duration
The treatment phase is defined as Cycles 1 
–12. Patients will be randomized to SOC +/-
midostaur in. Patients receiving midostaurin will receive study  drug for 12 cycles (max) or 
until patient experiences unacceptable toxicity , disease progression and/or treatment is 
discontinued at the discretion of the investigator or withdrawal of consent, whicheve r comes 
first.
6.2 Dose escalation guidelines
Not applicable
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose adjustments are 
permitted in order to allow the patient to continue t he study  treatment as listed in Table 6-2.
The toxicities listed will require treatment interruption of midostaurin treatment until recover y 
to ≤ Grade 2 or for a maximum of up to 21 consecutive days (amodification to this rule for 
nausea/vomiting is noted below). I n addition, dosing interruption is allow edto up to [ADDRESS_277848]-transplant period and the intent is to allow time to 
assess whether events are due to midostaurin, GVHD or other causes and to allow patients to 
remain on study .Patients may be re-challenged per the dose modification table . Any patient 
requirin g a longer delay  than 21 day s will be discontinued from the study .
Until durable engraftment has occurred, cytopenias may require transfusion support and/or 
growth factors and are permitted as per standard of care. If the cy topenia(s) are not considered 
related to midostaurin, the cause should be documented and dose holding and reduction of 
midostaurin is not required. If the cytopenia(s) is determined to be possibly  attributable to 
midostaurin, the dose modification guidelines should be followed.
 

[COMPANY_001] Confidential Page 42
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Dose adjustments are required for patients taking concomitant strong CYP3A4 inhibitors with 
midostaurin, refer to Section 6.4.[ADDRESS_277849] eCR F.
 

[COMPANY_001] Confidential Page 43
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Table 6-2 Criteria for interruption and re-initiation of midostaurin treatment
Recommended dose modifications for CPKC412AUS23
Investigations (Hematologic)
Neutropenia (ANC)
Grade 4 (ANC < 500/mm3) First event, hold midostaurin dose until recovery to Grade [ADDRESS_277850] event, patient should be discontinued if neutropenia is attributable to midostaurin
Thrombocy topenia
Platelet count < 15,000/mL First event, hold midostaurin dose until recovery to ≥ 20,000 per microliter then restart at 50mg 
b.i.d
Second event, hold midostaurin dose until recovery to ≥ 20,[ADDRESS_277851] event, patient should be discontinued if other causes for the thrombocy topenia cannot be 
determined
Other Hematologic Adverse Events
Grade 3 or 4 If a patient has not recovered from a new or worsening grade 3 or 4 hematologic toxicity 
(suspected relationship to midostaurin) to grade ≤ 2 within 21 days, he/she must be discontinued 
from the study.
 

[COMPANY_001] Confidential Page 44
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Recommended dose modifications for CPKC412AUS23
Investigations (Hepatic)*
Bilirubin, AST or ALT
Grade 3 (> 3.[ADDRESS_277852]) related to midostaurin 
(rather than VOD, GVH)If alternate causes of liver dysfunction have been managed, but liver dysfunction persists, hold 
midostaurin until recover yto Grade 2 then restart.
If this is felt to be related to study drug and the re -challenge results in a subsequent Grade 3 or 4 
elevation, then patient should be discontinued from treatment.
Pulm onary Infiltrates
Grade 3 or 4 Pulm onary infiltrate interruption of midostaurin for the remainder of the c ycle until the infiltrate 
resolves to ≤ grade.
Investigation (Gastro intestinal)
Nausea or Vomiting
Grade 2 If this develops despi[INVESTIGATOR_230725]-emetic therapy, hold midostaurin for 3 days (6 
doses) and resume midostaurin as tolerated; e.g. reduce the dose to 25mg b.i.d; if the event 
continues hold for 3 days (6 doses), resume at 25mg qd. If the event continues the patient should 
be discontin ued from treatment,
Grade 3 or 4 If this develops despi[INVESTIGATOR_230725] -emetic therapy, hold midostaurin until recovery to 
Grade 2 (or at least 3 days) then restart at 50mg b.i.d. If this is felt to be related to study drug and 
the re -challange results in a subsequent Grade 3 or 4 toxicity then the midostaurin dose may be 
reduced to 25mg b.i.d (50mg/day).
In the event of additional toxicity requiring dose modification refer to “Grade 3 or 4 -Other adverse 
events (Non -Hematologic) below.
 

[COMPANY_001] Confidential Page 45
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Recommended dose modifications for CPKC412AUS23
Other adverse events (Non -Hematologic)
Grade 3 or 4 If a patient has recovered to ≤ Grade 2 within 21 days of interrupting treatment, the midostaurin 
dose will be reduced to 25mg b.i.d (50mg/.day ). In the event of additional toxicity requiring dose 
modification, further dose reductions of midostaurin below 25mg b.i.d (50mg/day) will not be 
allowed. If the patient tolerates the lower dose of midostaurin (25 mg b.i.d) and considering the 
nature of the PK profile of midostaurin (concentration drops foll owing multiple doses), a dose 
increase back to 50mg b.i.d may  be attempted as tolerated.
If a patient has not recovered from any  grade 3 or 4 non -hematologic toxicity to < Grade 2 within 
21 days of interrupting treatment (with the exception of the dose mod ification stated above for 
Grade 2 -4 nausea and vomiting) will be discontinued from the study.
QTc Prolongation Refer to Table [ADDRESS_277853] preceding toxici ty. Common Toxicity Criteria for Adverse Events (CTCAE Version 4.0)
Investigator discrection to continue study drug (midostaurin) may be used for the following if it is felt that the AE is not study  drug related:
Cytopenias, AST/ALT elevation, Nausea or Vomiting. All of other AEs require dose modification per Table 6 -2.
 

[COMPANY_001] Confidential Page 46
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
6.3.[ADDRESS_277854]. If a patient requires a dose delay  of > [ADDRESS_277855] died or withdrawn from the study  prior to this time point. Prior to database lock, 
an additional OS and RFS update will be requested for all living patients.
6.3.3 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility  criteria as well as specific dose modification and stoppi[INVESTIGATOR_63956]. Recommended guidelines for proph ylactic or supportive treatment 
for expected toxicities, includin g management of study -drug induced adverse events, i.e., 
nausea and vomiting are provided in Section [IP_ADDRESS].1 . Refer to preclinical toxicity  and or 
clinical data found in the Investigator’s Brochure.
6.[ADDRESS_277856] be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications taken within 28 days prior to 
randomization and all concomitant medications/therapi
[INVESTIGATOR_230737]/Non -Drug Therap y eCRF.
Other anticancer agents including chemotherapy , radiation therapy , or biologic response 
modifiers, e.g. FLT3 inhibitors (including sorafenib) , are not permitted prior to relapse. Donor 
Lym phocy te Infusion (DLI)is not allowed except for viral specific Cytotoxic T Cells (CTLs)
or low dose CTLs for EBV lymphoproliferative disorders (i.e., DLI for worsening chimerism 
is not allowed prior to relapse). No other investigational drug is allowed during t he stud y.
6.4.1 Permitted concomitant therapy
[IP_ADDRESS] Supportive care
In general, the use of any concomitant medication/therapi[INVESTIGATOR_230738].
Based on preclini cal investigations demonstrating that midostaurin is an inhibitor of P-gp 
though not a good substrate, the interaction between midostaurin and P-gp subtrate, 
 

[COMPANY_001] Confidential Page 47
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
daunorubicin was studied in the clinical study  [CPKC412A2106]. The pharmacokinetics of 
daunorubici n did not show any notable modification when coadministered with midostaurin.
[IP_ADDRESS].1 Anti-emetic treatment with midostaurin
Nausea and vomiting are commonly  reported in studies with midostaurin administration. 
These events are more frequent during combination the rapy and are dose -dependent.
Prophy laxis for the prevention of nausea and vomiting is highly  recommended. The kind and 
dose of anti-emetic drug should be chosen as per investigator discretion. Patients may be 
given ondansetron hydrochloride or granisetron. Other anti-emetics such as metoclopramide, 
methotrimeprazine, cyclizine, prochlorperazine or tropi[INVESTIGATOR_230739].
Since nausea (and in some cases vomiting) may  still occur 1 -3 hours after the dose, additional 
anti-emetics after midostaurin dosing may be required. In these cases, promethazine 
(phenergan), prochlorperazine (compazine), lorazepam (ativan) or other anti-emetics can be 
used ½ hour to 1 hour after study  drug as per investigator discretion.
If patients suffer from Grade 3 or 4 severe nausea and/or vomiting, refer to Section 6.3.
[IP_ADDRESS].2 Anti-diarrhetic treatment with midostaurin
For the management of diarrhea, oral loperamide can be administered. An initial dose of 4 mg 
followed by 2
 mg every 4 hours or after every  unformed stool (maximum of 16 mg/day) is 
suggested. However, the kind and dose of anti-diarrheal should be chosen per investigator 
discretion.
[IP_ADDRESS] Prophy laxis and treatment management of GVHD and sy stemic 
immunosuppressive medications
As per standard of care, GVHD proph ylaxis regimens are recommended (e.g., mycophenolate 
mofetil, cy closporine, methotrexate, tacrolimus, sirolimus) and should follow standard of care 
at your institution.
If patients develop activ e GVHD, standard of care per your institution should be followed and 
steroids are permitted. While some of these medications are substrates of CYP3A4, 
midostaurin has minimal impact on CYP3A4 substrates (see Section [IP_ADDRESS].1 and 
Section 6.4.2 on PK). The recommendation is to avoid the co-administration of a strong 
CYP3A4 inhibitor or a strong and moderate CYP3A4 inducer with midostaurin. Levels of 
cyclosporine, tacrolimus, sirolimus or cyclosporine should be monitored closel y, as per 
standard of care.
[IP_ADDRESS] Contraceptives w ith midostaurin
Women must avoid breast- feeding during study treatment, and all women of childbearing 
potential will be required to empl oy a  h ighly effective method of birth control which is 
defined as a birth control which results in a low failure rate (i.e. less than 1% per year) when 
used consistently  and correctl y. This has to be employ ed for the duration of the study  and for 
[ADDRESS_277857] study  because of the long half- life of the metabolite, CGP52421.
 

[COMPANY_001] Confidential Page 48
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Women of child -bearing potential, defined as all women physiologically  capable of becoming 
pregnant, unless they are using highl y effective methods of contraception during dosing and 
for3 months of midostaurin medication. Highl y effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation methods) 
and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I n case of 
oophorectom y alone, only  when the reproductive status of the woman has been confirmed 
by [CONTACT_104]
Male sterilization (at least 6 months prior to screening). For female subjects on the study  
the vasectomized male partner should be the sole partner for that subject .
Combination of any two of the following (a+b or a+c, or b+c):
a.Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
exam ple hormone vaginal ring or transdermal hormone contraception.
b.Placement of an intrauterine device (IUD) or intrauterine s ystem (IUS)
c.Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/fil m/cream/vaginal suppository
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of 3 months before taking stud y treatment.
Sexually  active males unless they use a condom during intercourse while taking drug andfor 
5months after stoppi[INVESTIGATOR_230736]. They  should not father a child in this period. 
A condom is required to be used also by [CONTACT_230769].
6.4.2 Permitted concomitant therapy  requiring caution and/or action
[IP_ADDRESS] Concomitant medications with potential for CYP3A 4 interactions
[IP_ADDRESS].1 Midostaurin can be impacted by [CONTACT_097]3A4 inhibitors and inducers:
Midostaurin is a sensitive substrate of CYP3A4 [CPKC412A2109]; [CPKC412A2110] ,. This 
indicates that the pharmacokinetics of midostaurin may be influenced by [CONTACT_230770]3A4.
[IP_ADDRESS].2 Interactions with inhibitors of Cytochrome P450 3A4
In a healthy  volunteer drug-drug interaction study  where midostaurin was co-administrated 
with the potent CYP450 3A4 inhibitor ketoconazole, the exposure of midostaurin increased 
by 10-fold (90% confidence interval 7.4-14.5) [CPKC412A2109]. Based on the above data, 
administration of concomitant strong CYP3A4 inhibitors with midostaurin should be avoided 
and alternative therapeutics which does not strongl y inhibit CYP450 3A4 activity  should be 
considered. If there are no other treatment 
options for the patient (i.e life-threatening 
infection), a compensatory reduction in the dose of midostaurin is warranted.
 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
The dose adjustment of midostaurin is aimed to achieve similar exposure to the range 
observed of midostaurin 50mg twice daily  without the strong inhibitor. As a result, a dose 
reduction of 7-fold based on the lower bound of the confidence interval of the ratio of [AUC 
midostaurin with ketoconazole/AUC midostaurin without ketoconazole] is recommended 
[CPKC412A2109]. Hence the prescribed dose reduction during the time of a concomitant 
strong CYP3A4 inhibitor (see list below) is midostaurin 25 mg every  other day .
If the strong CYP3A4 inhibitor is discontinued, approximately  2
 to 3 days should elapse 
before increasing the midostaurin dose back to the dose prior to initiation of the strong 
CYP3A4 inhibitor.
Strong CYP3A4 inhibitors: clarithromycin, telithromycin, troleandomycin, indinavir, 
lopi[INVESTIGATOR_054], nelfinavir, ritonavir, saquinavir, tipranavir, itraconazole, ketoconazole, 
posaconazole, voriconazole, boceprevir, telaprevir, cobicistat, conivaptan, nefazodone.
Moderate CYP3A4 inhibitors: Caution should be exercised for patients receiving moderate 
CYP450 3A4 inhibitors. A list of moderate CYP450 3A4 can be found on:
http://medicine.iupui.edu/clinpharm/ddis/main- table/
[IP_ADDRESS].3 Interactions with moderate and strong inducers of Cytochrome P450 3A4
In a healthy  volunteer drug-drug interaction study  where midostaurin was co-administrated 
with the potent CYP450 3A4 inducer rifampi[INVESTIGATOR_2513], the Cmax and AUC of midostaurin 
decreased by 73% and 94%, respectivel y[CPKC412A2110] . To avoid sub-therapeutic 
exposure to midostaurin, moderate or potent CYP450 3A4 inducers should not be 
coadministered.
Strong CYP3A4 inducers: avasimibe, carbamazepi[INVESTIGATOR_050], mitotane, phenobarbital, 
phenytoin, rifabutin, rifampin (rifampi[INVESTIGATOR_2513]), St. John's wort (hypericum perforatum);
Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, genistein, modafinil, 
nafcillin, ritonavir, talviraline, thioridazine, tipranavir.
[IP_ADDRESS].[ADDRESS_277858] the pharmacokinetics of other CYP3A4 
substrates:
Midostaurin, administered as a single dose or in multiple doses, did not appear to affect the 
concentrations of midazolam or its metabolite 1’-hydroxymidazolam [CPKC412A2112] . As a 
result, midostaurin is neither a CYP3A4 inhibitor nor a CYP3A4 inducer in vivo in humans at 
clinically  relevant conditions. Therefore, midostaur in is not expected to affect the 
pharmacokinetics of other CYP3A4 substrates.
[IP_ADDRESS] Concomitant anti- infective prophylaxis and treatment
It is highl y recommended to avoid concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, 
itraconazole, voriconazole, posac onazole). The suggested antifungal regimens from a drug 
metabolism perspective is described below:
Prophy laxis
Fluconazole (moderate CYP3A4 inhibitor)
Micafungin
 

[COMPANY_001] Confidential Page 50
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
If a patient requires active treatment for a fungal or mold infection and and the only  treatme nt 
options isan azole thatis a strong CYP3A4 inhibitor then the suggested agents from a drug 
metabolism and safet y perspective include:
Treatment
Voriconazole
Posaconazole
These are both strong CYP3A4 inhibitors and will likely  increase midostaurin concen trations, 
therefore, if there are no other treatment options to treat the infection, a dose reduction of 
midostaurin is required .See details in Section 6.4.[ADDRESS_277859] Number (Subject No.), that is 
assigned when the patient is first 
presented for screening and is retained as the primary  
identifier for the patient throughout his/her entire participation in the trial. The Subject No. 
consists of the 4-digit center number (Center No.) (as assigned by [CONTACT_37238]) with a sequential 5-digit patient number suffixed to it, so that each subject 
is numbered uniquely  across the entire database. Upon signing the informed consent form, the 
patient is assigned to the next sequential Subject No. available to the investigator through the 
Interactive Web Response System (IWRS) . Once assigned to a patient, a patient number will 
not be reused. If the patient fails to be assigned to treatment for any reason, the reason for not 
being assigned to treatment will be captured through the IWRS system. Patients cannot be re-
randomized.
6.5.2 Treatment assignment or randomization
This is a randomized (1:1) two-arm, open -label study  with standard of care with or without
(+/-
)midostaurin 50mg twice dail y for up to 12 cycles.
The two arms will be: (1) Standard of Care and (2) Standard of Care plus midostaurin.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased. A patient randomization list will be produced by [CONTACT_230771]  (IWRS) provider using a validated system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms.
After all assessments have been completed , all patients who fulfill all inclusion/exclusion 
criteria will be randomized via IWRSon C1D1 to one of the treatment arms. The investigator 
or his/her delegate will call or log on to the IWRS and confirm that the patient fulfills all the 
inclusion/exclusion criteria. The IWRS will assign a randomization number to the patient, 
which will be used to link the patient to a treatment arm. The randomization number will be 
communicated by [CONTACT_230772], to the investigator and or delegate for 
patient designation to the trial.
 

[COMPANY_001] Confidential Page 51
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
6.5.3 Treatment blinding
Not applicable –Open label treatment
6.6 Stud y drug preparation and dispensation
Midostaurin will be administered by [CONTACT_230773] 50 mg (i.e. 4 capsules of 
midostaurin 25 mg in two divided doses) beginning on Day  [ADDRESS_277860] shown midostaurin to be better 
tolerated (with respect to short term nausea and vomiting) if taken following meals. Patients 
should be instructed to swallow capsules whole and not chew capsules. An interval of 
approximately  [ADDRESS_277861] the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages prescribed to the patient and all dose changes during the study 
must be recorded on the Dosage Administration Record eCRF.
Table 6-3 Preparation and dispensing
Study treatments Dispensing Preparation
Midostaurin (PKC412) Gelatin capsules including instructions 
for administration are dispensed by 
[CONTACT_230774].
Patients will be provided with adequate 
supply of study treatment for self -
administr ation at home until at least 
their next scheduled study visit.Midostaurin is packaged in blister 
packs. Midostaurin should not be 
removed from the blister pack 
until the patient is ready to take 
the scheduled dose. Upon 
opening a blister pack, patients 
may notice a pungent odor but 
will dissipate.
6.6.1 Study drug packaging and labeling
Midostaurin will be supplied by  [CONTACT_230775] . The study 
drug will be provided as open label bulk and packed in child resistant blisters. The drug 
should be stored in the blister pack until use andno further preparation of the study  drug is 
needed .Upon opening a blister pack, patients may notice a pungent odor. The odor is due to 
ethyl thiogl ycolate that forms when ethanol in the capsules 
interacts with the thermostabilizer 
in the foil. The capsules are not affected, and the odor will dissipate. Each capsule contains 25 
mg of midostaurin. Medication labels will comply with the legal requirements of each country 
and be printed in the local l anguage.
One component of the packaging has a 2- part label. I mmediatel y before dispensing study  drug 
to the patient, investigator staff will detach the outer part of the label from the packaging and 
affix it to the source document (Drug Label Form) contain ing that patient’s unique patient 
number.
 

[COMPANY_001] Confidential Page 52
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Table 6-4 Packaging and labeling
Study drug Packaging Labeling (and dosing frequency)
Midostaurin (PKC412) 25mg soft gelatin capsules in 
child resistant blistersLabeled as PKC412 25mg
Study treatment packaging has a 2- part 
label.
6.6.2 Drug supply  and storage
Study  drug (Midostaurin) must be received by [CONTACT_121937], handled 
and stored safel y and properly , and kept in a secured location to which only the investigator 
and designated site personnel have access. Upon receipt, the study drug should be stored 
accor ding to the instructions specified on the drug labels . Do not store above 25° C.
Table 6-5 Supply  and storage of study  treatments
Study treatment Supply Storage
Midostaurin (PKC412) Centrally supplied by [CONTACT_230776] 25° C.
6.6.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
The data that will be collected on study  drug and other therapy  use will provide information 
about drug exposure. These data should correspond to the information requested on the eCRFs 
entitled Dosage Administration Record (used for midostaurin administration only); 
Concomitant Medications; any  other eCRFs specific to the project and/or patient diaries.
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit 
and information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
patient visit.
Compliance will be assured by [CONTACT_230777]/her designee, and will be verified by [CONTACT_230778]412 and two 
metabolites in the plasma.
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  drug in a drug accountability  log. Drug accountability  will be noted by [CONTACT_5364] . Patients will be asked to return 
all unused study  drug and packaging on a regular basis, at the end of the study  or at the time 
of study  drug discontinuation.
[IP_ADDRESS] Handling of other study  treatment
Not applicable.
 

[COMPANY_001] Confidential Page 53
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
6.6.[ADDRESS_277862] part y, as 
appropriate. On site disposal or destruction is permitted upon [COMPANY_001] review and agreement 
with the loc al policy /SOP.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be supported in the patient’s source 
documentation.
No CRF will be used as a source document.
 

[COMPANY_001] Confidential Page 54
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Table 7-1 Visit evaluation schedule
Protocol 
Section 
7.2 (if 
applicable)Screening Cycle 1 Day 30 –
Day [ADDRESS_277863] 
HSCTSubsequent 
Cycles (2 -12)
*Refer to 
Section for 
FrequencyEnd of 
study  
treatment 
(EoT)Follow 
upSurvival 
follow upStudy  
Completion 
Evaluation
Visit Number1 2 3 4 5-15 16 (777) 501, [ADDRESS_277864] n/a n/a n/a
Obtain Informed Consent X
IWRS/IRT X X X X X X X X X
Randomization X
Patient history X
Demography X
Inclusion/exclusion criteria X X
Relevant medical history/current 
medical conditionsX
Diagnosis and extent of cancer X
Prior antineoplastic therapy X
Prior concomitant medications X
Safety
Serious Adverse EventsX X X X X X X [ADDRESS_277865] EOT
Concomitant Medications X X X X X X
Physical examination [IP_ADDRESS] . X X X X X X
Vital signs [IP_ADDRESS] . X X X X X X
Height [IP_ADDRESS] . X X
Weight [IP_ADDRESS] . X X X X X
 

[COMPANY_001] Confidential Page 55
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Protocol 
Section 
7.2 (if 
applicable)Screening Cycle 1 Day 30 –
Day [ADDRESS_277866] 
HSCTSubsequent 
Cycles (2 -12)
*Refer to 
Section for 
FrequencyEnd of 
study  
treatment 
(EoT)Follow 
upSurvival 
follow upStudy  
Completion 
Evaluation
Visit Number1 2 3 4 5-15 16 (777) 501, [ADDRESS_277867] n/a n/a n/a
Performance status [IP_ADDRESS] . X X X
Laboratory assessments [IP_ADDRESS] . X X X X X
Hematology [IP_ADDRESS] . X X X X X X
Chemistry [IP_ADDRESS] . X X X X X
Urinalysis [IP_ADDRESS] . X
Coagulation [IP_ADDRESS] . X
Thyroid (T4 and TSH)[IP_ADDRESS] . X C2D1, C6D1 
and C12D1X [ADDRESS_277868] EOT
Pregnancy [IP_ADDRESS].[ADDRESS_277869] x -ray/CT Scan [IP_ADDRESS] . X
ECG [IP_ADDRESS].1 . X X X X X
MUGA/ECHO [IP_ADDRESS].2 . X C3 and C6 X
Pharmacokinetics
PK Sampling (study maintenance) [IP_ADDRESS] . X X X
Biomarkers 7.2.4 .
Central Determination of FLT3-ITD [IP_ADDRESS] . X
GVHD assessment X X X X X
 

[COMPANY_001] Confidential Page 56
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Protocol 
Section 
7.2 (if 
applicable)Screening Cycle 1 Day 30 –
Day [ADDRESS_277870] 
HSCTSubsequent 
Cycles (2 -12)
*Refer to 
Section for 
FrequencyEnd of 
study  
treatment 
(EoT)Follow 
upSurvival 
follow upStudy  
Completion 
Evaluation
Visit Number1 2 3 4 5-15 16 (777) 501, [ADDRESS_277871] n/a n/a n/a
Study Drug dispensation and review X X X X X
SOC Study Drug administration X X X X X
Bone marrow7.2.4.1 . X C6D1 and 
C12D1
Archived stored frozen mononuclear 
cells / DNAX-
historical
 

[COMPANY_001] Confidential Page 57
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
7.1.[ADDRESS_277872] be signed prior to any screening procedures begin. Patients should be 
randomized onto the trial within 14days from date of screening ; randomization will occur
after all assessme nts have been completed on C1D1 .
Patients that do not meet eligibility  criteria at initial screening, but have met eligibility  criteria 
by [CONTACT_2006] [ADDRESS_277873] met eligibility  by [CONTACT_2006]  60.
[IP_ADDRESS] Eligibility  screening
Following registering in the IWRS for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibility  check will be embedded in the IWRS 
system. Please refer and comply
 with detailed guidelines in the I WRS manual.
[IP_ADDRESS] Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatment for any reason will 
be considered a screen failure. All data for screen failures are entered intothe IWRSsystem, 
including the reason for not being started on treatment Screen failure data will not beentered 
into the clinical databa se unless the patient experienced a Serious Adverse Event during the 
Screening Phase (see Section 8for SAE reporting details). All screen failure data from the 
IWRS will be exported to a SAS dataset fo r final data review and archiving.
The reasons for screen failures may  include the following:
Unacceptable medical history /concomitant diagnosis
Intercurrent medical event
Unacceptable laboratory  value(s)
Unacceptable test procedure result(s)
Did not meet diagnostic/severit y criteria
Unacceptable use of excluded medications/therapi[INVESTIGATOR_230740]
[IP_ADDRESS] Patient demographics and other baseline characteristics
Baseline patient data pertaining to demographic information and relevant medical history  
relate d to study  indication should be documented accordingl y in the eCRFs to include , but not 
limited to the following information:
Date of birth
Age
Sex
Race
Relevant medical history and if active at start of study
 

[COMPANY_001] Confidential Page 58
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Date of diagnosis
Performance status
FLT3 -ITD mutation status
Any additional mutation information, if known
Cytogenetics
Date of first Complete R emission (CR1)
Date of Transplant
A detailed history  of allprior antineoplastic therapi[INVESTIGATOR_014], such as medications for treatment of 
leukemia must be recorded on the eCRF including:
Medication name/ Non -drug therap y
Dose
Start/End date
Best response
Additionally  all other medications and significant non-drug therapi[INVESTIGATOR_14939] [ADDRESS_277874] be recorded on the eCRF page and upda ted on a 
continual basis if there are any new changes to the medication. Medications include phy sician 
prescribed, over-the-counter medications, vitamins, and herbal and alternative therapi[INVESTIGATOR_014]. 
Information to be collected on concomitant medications/signific ant non
-drug therapi[INVESTIGATOR_230741]:
Medication/Non- drug therap y trade name
[CONTACT_230795]/End date and if continuing at time of examination
In addition to the general demographic and relevant medical history  information, study  
specific information will be collected during the screening period as indicated in the 
assessment schedule ( Table 7 -1) in order to determine eligibility  of the patient.
7.1.2 Treatment and study  period
The treatment period for all patients regardless of treatment assignment is defined as Cy cles 1 
–
12.
For the treatment period patients will be randomized to SOC +/-midostaurin. Patients 
receiving SOC + midostaurin will receive midostaurin for 12 cycles (max) oruntil patient 
experiences unacceptable toxicity , relapse, death and/or treatment is discontinued at the 
discretion of the investigator or withdrawal of consent, whichever comes first.
It is likely  that patients receiving SOC may have alread y began this treatment prior to 
randomizing onto the trial as part of his/her post HSCT standard of care treatment regimen. 
Any medications that began prior to the randomization/treatment period will be captured in 
the medical history  and subsequently  captured on the Concomitant Medication page during 
the treatment period. If the medication is still being taken at the end of the treatment phase, 
the medication should be recorded as ongoing.
Patient visits will occur monthly  for one year during the Treatment Period (Cycles 1-12). 
Patients will continue in the Follow -up Phase and have assessments for at least 24 months 
 

[COMPANY_001] Confidential Page 59
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
post HSCT. Hematology Lab Panels will be collected on average every  two months between 
Follow up assessments to evaluate relapse in addition to survival status.
Patients that have not relapsed, died or withdrawn at [ADDRESS_277875] withdrawn from the study . Prior to database lock, an 
additional OS and RFS update will be requested from all living patients.
Table 7-2 Treatment visit frequency  and windo ws
Visits Frequency Window
Cycle 1 D1, 3 and 15 +/-1 day
Cycles 2 -12 Monthly, D1 +/-5 day s
End of Treatment (EOT) SOC:
C12 D28 or at first relapse or 
discontinuation from the study
SOC + Midostaurin:
C12 D28 or at time of midostaurin 
treatment discontinuation+/-7 day s
7.1.3 End of treatment visit including study  completion and premature 
withdrawal
[IP_ADDRESS] End of Treatment (EOT)
Patients may voluntaril y withdraw from the study  or be dropped from it at the discretion of 
the investigator at an y time.
In the SOC arm, the End of Treatment (EOT) is considered as the end of cycle 12, the date 
of first relapse or the date of discontinuation, whichever occurs first.
In the SOC + Midostaurin arm, the EOT is defined as the last study  drug (midost
aurin) 
intake.
At the time patients discontinue study  treatment; a visit should be scheduled as soon as 
possible, an End of Treatment (EOT) Phase eCRF page should be completed, giving the date 
and primary  reason for a patient’s premature withdrawal from th e study
Patients may  be withdrawn from treatment if any of the following occur:
Adverse events
Abnormal laboratory  values
Abnormal test procedure result
Subject withdrew consent
Lost to follow up
Administrative problems
Death
Relapse
 

[COMPANY_001] Confidential Page 60
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Treatment duration com peted as per protocol
Protocol deviation
At minimum, patients who discontinue study  drug/from the study ,including those who refuse 
to return for a final visit will be contact[CONTACT_230779] 30days following the 
end of treatment.
Patients who discontinue study  treatment also should return for relapse and follow up 
assessments at visits and should not be considered withdrawn from the study . If patients 
refuse to return for these visits or are unable to do so, every  effort should be made to contact 
[CONTACT_18622] a knowledgeable informant by [CONTACT_230780]/or 
survival status.
[IP_ADDRESS] Study Evaluation Completion (SEC)
If a patient discontinues study  treatment, but continues study  assessments, the patient remains 
on study until such time as he/she completes protocol criteria for ending study  assessments. 
At that time, the reason for study  completion should be recorded on the Study  Evaluation 
Completion CRF (SEC) page. End of treatment/Premature withdrawal visit is not considered 
as the end of the stud y.
The reasons for stud y evaluation completion may include , but not limited to the following:
Subject withdrew consent
Lost to follow -up
Administrative problems
Death
Relapse
Protocol Deviation
Follow up phase completed as per protocol
7.1.[ADDRESS_277876] dose of midostaurin for 
patients in the SOC+ midostaurin arm. For patients in the SOC arm, all patients must have 
safet yevaluations 30 days after the end of Cycle 12/first relapse/withdrawal, whichever 
comes first.
During Follow up, patients will be asked to have a hematology  panel every  [ADDRESS_277877] not relapsed, died or withdrawn 
 

[COMPANY_001] Confidential Page 61
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
at 24 months will be asked to provide quarterly  hematology  panels until the study  ends. For 
all living patients, an additional OS and RFS update will be requested prior to database lock.
The assessment schedule is outlined in Table 7-3.
Table 7-3 Follow up assessment frequency  and windo ws
Time Point Assessment Window
Patients that prematurely discontinue 
from treatment phase prior to 
completion of Cy cle 12
Every [ADDRESS_277878]Survival
Hematology Panel
Bone Marrow (BM) at 
investigator’s discretion+/-14 days
Patients that complete Cy cle 12
Every 2 months from EOT until 24 
monthsSurvival
Hematology Panel
BM at investigator’s discretion+/-[ADDRESS_277879] not relapsed at 24 
months
Quarterly until the last patient has 
been followed for 24 monthsSurvival
Hematology Panel+/-21 days
Relapse Hematology Panel
BM+/-[ADDRESS_277880] to 
follow -up, the investigator should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, 
etc.
7.2 Assessmen t types
7.2.1 Efficacy  assessments
Complete Response (CR) is when the following levels are detected in the Peripheral Blood 
(PB); ANC ≥ 1000/uL ; Platelet count ≥ 100K and no circulating leukemic my eloblasts in 
peripheral blood and Bone Marrow (BM) has adequate cellularit y, BM blast count ≤ 5% 
and no auer rods detected.
Relapse following complete response is defined as reappearance of leukemic blasts in the 
peripheral blood or finding more than 5% blasts in the bone marrow.
Relapse Free Survival (RFS) assesses th e clinical benefit of remaining in remission free 
from relapse or death due to the disease. It is defined as the time from transplant to relapse 
or death due to the disease.
Disease Free Survival (DFS) assesses the clinical benefit of remaining in remission free 
from relapse or death from any  cause. It is defined as the time from transplant to relapse or 
death from an y cause. This is aligned with [COMPANY_001] AML  guidance and FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, 
2007). If a patient has more than one event (e.g. relapse and death) then the earliest date 
will be taken into account.
Overall Survival (OS) is defined as the time from transplant to death from any  cause.
 

[COMPANY_001] Confidential Page 62
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
[IP_ADDRESS] Bone marrow aspi[INVESTIGATOR_230742] 7-4to assess Efficacy  
endpoints.
Table 7
-4 Bone marro w collection plan
Procedure Screening/During Treatment Period During Follow up
Bone MarrowResults from Initial diagnosis required for 
eligibility
Between D30 –[ADDRESS_277881]
Cycle 6
Cycle 12Relapse and/or investigator 
discretion
The BM aspi[INVESTIGATOR_230743]. If required in case of inspi[INVESTIGATOR_230744], core biopsy  should be 
performed.
For response assessment it is required that bone marrow assess ment and the corresponding 
blood assessment (CBC) is done within a 5 day  window.
7.2.2 Safety  and tolerability assessments
The assessment of safet y will be based mainly  on the frequency  of Adverse Events (AEs) , on 
the number of laboratory  values summarized by [CONTACT_230781]-relapse mortality
(NRM) .
Summary  statistics will be provided for data from other tests (e.g. electrocardiogram or vital 
signs) and an y other information collected will be listed as appropriate.
All AEs recorded during the study  will be summarized by [CONTACT_2939]. The incidence of 
treatment -emergent AEs (new or worsening from baseline) will be summarized by [CONTACT_230782], preferred term, severit y (based on CTCAE grades), type of AE and 
relationship to the study  drug. Deaths reportable as SAEs and nonfatal SAEs will be listed by 
[CONTACT_230783] b y type of AE.
For further details on AE collection and reporting, refer to Section 8.
All assessments must be drawn PRIOR to administration of study  treatment (of that day ).
Non-relapse mortality  assesses the other causes of death not due to disease or relapse (e.g., 
late toxicity  due to GVHD). It is calculated from the date of transplant to the date of patient 
death due to 
reasons other than relapse.
[IP_ADDRESS] Physical examination
A physical examination must be performed at the screening visit, Day 1 and 15 of Cycle 1, 
Day 1 of each subsequent cy cle, and on the day  of discontinuation/end of treatment (EOT).
Information about the physical examination must be present in the source documentation at 
the study  site.
Significant findings that were present prior to the signing of informed consent must be 
included in the Medical History  page on the patient’s eCRF. Significant new findings that
 

[COMPANY_001] Confidential Page 63
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
begin or worsen after informed consent must be recorded on the Adverse Event page of the 
patient’s eCRF.
[IP_ADDRESS] Vital signs
Vital signs include temperature, respi[INVESTIGATOR_2842], blood pressure and pulse and will be taken in 
the sitting position. Vitals will be meas ured at Screening, Cy cle 1 Day  1, 3, 15, Day  1 of each 
subsequent cy cle and at End of Treatment (EOT)
Information about vital signs must be recorded in the source document at the study  site. 
Significant findings present prior to the start of study  drug must be in the Relevant Medical 
History / Current Medical Conditions eCRF. Significant finding made after the start of study  
drug which meet the definition of an adverse event must be recorded on the Adverse Event 
eCRF.
[IP_ADDRESS] Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured. Height will be measured at Screening and on 
the day of discontinuation/end of treatment (EOT). Weight will be measured at Screening, 
Day 1  a nd 15 of Cycle 1, Day 1  of each subsequent cycle, and on the day of 
discontinuation/end of treatment (EOT).
[IP_ADDRESS] Performance status
ECOG Performance Status will be assessed at Screening, Day 1  of Cycle 1 and at End of 
Treatment (EOT).
Table 7-5 ECOG Performance Status
Grade ECOG
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in phy sically  strenuous activity but ambulatory and able to carry  out work of a 
light or sedentary nature, e.g., light house work, office work
2 Ambulator y and capable of all selfcare but unable to carry  out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confin ed to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
[IP_ADDRESS] Laboratory  evaluations
Frequency  of evaluations must be performed according to the Visit Schedule and Assessment , 
Table 7-1, and parameters outlined in Local Clinical laboratory  parameters collection plan
Table 7-6. Anal yses and assessments are to bedone locally  and results transcribed to the 
eCRF. When abnormal laboratory  values or test results constitute an 
adverse event (i.e., 
induces clinical signs/symptoms or requires therapy ) they must be recorded on the Adverse 
Events eCRF.
 

[COMPANY_001] Confidential Page 64
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
All laboratory  values must be drawn PRIOR to randomization /first dose of study  drug. 
Every  effort should be made to obtain screening laboratory  values 14days prior to study  entry 
and these need then not be repeated at study  entry if performed within 14days of the initial 
dose of midostaurin. All other laboratory  evaluations must be performed within +/- 48 hours 
of a study  visit.
If administration of midostaurin is interrupted due to Grade [ADDRESS_277882] Name [CONTACT_6674]/During 
TreatmentDuring Follow -
up
Hematology Total white blood cell count with differential 
(neutrophil count including bands, 
lymphocy te, monocyte, eosinophil, 
basophil/mast cell, % and absolute blast 
count, and early m yeloid forms), 
hemoglobin, hematocrit, platelet count and 
reticulocyte count.Screening
Cycle 1 D1,15
Cycle 2 -12; D1
EOTRefer to Table 7 -3
after EOT
Chemistry Albumin, Alkaline phosphatase, ALT 
(SGPT), AST (SGOT), Bicarbonate, 
Calcium, Chloride, Creatinine, Creatine 
kinase, Sodium, Potassium, phosphorus, 
magnesium, glucose, Direct Bilirubin, 
Indirect Bilirubin, Total Bilirubin, Total 
Cholesterol, LDL, HDL, Total Protein, 
Trigly cerides, Blood Urea Nitrogen (BUN) 
or Urea, Uric Acid, Lipase and Am ylase.Screening
Cycle 1 D1,15
Cycle 2 -12; D1 
EOTRefer to Table 7 -3
after EOT
Urinalysis Macroscopic Panel (Dipstick) (Color, 
Bilirubin, Blood, Glucose, Ketones, 
Leukocytes esterase, Nitrite, p H, Protein, 
Specific Gravity)
Any significant findings on dipstick will be 
followed up with a microscopic evaluation 
where bacteria, W BC, RBC sediments will 
also be measured.
Microscopic Panel (Red Blood Cells, White 
Blood Cells, Bacteria, and additional 
findings)Screening or more 
frequent if 
clinically indicated.n/a
Coagulation Prothrombin time (PT), International 
normalized ratio [INR]), Partial 
thromboplastin time (PTT) or Activated 
partial thromboplastin time (APTT)Screening or more 
frequent if 
clinically indicatedn/a
Thyroid T4 [free], TSH Screening, C2D1, 
C6D1, C12D1 or 
more frequent if 
clinically indicated30 Days after end 
of treatment 
(EOT)
Note: All efforts should be made to collect the labs prior to dosing. Fasting is not required.
 

[COMPANY_001] Confidential Page 65
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
[IP_ADDRESS].[ADDRESS_277883] ≤ [ADDRESS_277884] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate, history  of vasomotor sy mptoms).
Note: 
Barrier contraceptives must be used throughout the study  in both sexes.
[IP_ADDRESS] Radiological ex aminations
A screening chest image; Chest x-ray (CXR) or CT scan must be performed to assess study 
eligibility .If a CXR or CT scan was done within 14 days of screening assessments then it 
does not need to be repeated.
[IP_ADDRESS] Cardiac assessments
[IP_ADDRESS].1 Electrocardiogram (ECG)
A standard 12 lead ECG will be performed
at screening
at Cy cle 1: Day  1 (pre -dose)
at Cy cle 1: Day  3
at Cy cles 2 -12: Day  1
End of Treatment (EOT) or Treatment Discontinuation
Currently  the effect of midostaurin on QTc interval prolongation is not fully characterized. 
Therefore, all patients experiencing a post baseline prolonged QTc interval must have 
potassium and magnesium checked and any electroly tes imbalances corrected. Additionally , 
the investigator should consider the risk benefit of any conco mitant medications that may 
prolong the QTc interval. For the purpose of this trial, the correction formula according to 
Fredericia, i.e. QTc Fis being referred to - wherever QTc is mentioned.
The baseline ECG QTc interval must be less or equal than 450 ms.
 

[COMPANY_001] Confidential Page 66
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Table 7-7 ECG collection plan
QTc Interval Action
ECG > 450msec If the ECG shows a QTc interval greater than 450 msecs at 
screening or during the trial, triplicates should be performed, one 
minute apart to confirm the finding (after replacement of any 
electrolyte imbalance). If 2/3 or 3/3 of the ECGs confirm the QT 
prolongation (i.e. QTc interval > 450 msecs) the patient must not 
be included into the trial.
> 450 msecs and ≤ [ADDRESS_277885] any 
abnormalities. If possible, stop any medications that may prolong 
the QTc interval. Continue midostaurin at the same dose.
QTc interval > 470 msecs and 
≤[ADDRESS_277886] any 
abnormalities. If possible, stop any medications that may prolong 
the QTc interval. Decrease midostaurin to 25 mg twice daily for the 
remainder of the cycle/or for 2 weeks. Resume midostaurin at the 
initial dose in the next cyc le provided that QTc interval improves to 
≤ 470 msecs.
> [ADDRESS_277887] any 
abnormalities. Hold or interrupt midostaurin for the remainder of 
the cycle, and, if possible, stop any medications that may prolong 
the QTc interval. If QTc improves to ≤ [ADDRESS_277888] be made by a qualified physician and documented on the 
ECG eCRF page. Each ECG tracing should be labeled with the study  number, patient initials 
(where regulations permit) , patient number, date, and kept in the source documents at the 
study  site. Clinically  significant abnormalities present when the patient signed informed 
consent should be reported on the Medical History eCRF page. Clinicall y significant findings 
must be discussed with [COMPANY_001] prior to enrolling the patient in the study. New or worsened 
clinically  significant findings occurring after informed consent must be recorded on the 
Adverse Events eCRF page.
[IP_ADDRESS].2 Cardiac imaging -
MUGA (multiple gated acquisition) scan or 
echocardiogram
An echocardiogram or MUGA scan must be performed
at scr eening prior to Day  1
at Cy cle 3, 6
at the EOT visit
The baseline left ventricular ejection fraction (LVEF) must be >45% for eligibility  and the 
patient must not meet the criteria for congestive heart failure NYHA classification grade III or 
IV to be elig ible for the trial.
The modality  chosen at screening (echocardiogram or MUGA) must remain constant 
throughout the study . These assessments may be repeated at the investigator’s discretion if 
there are signs or symptoms of cardiotoxicity  through the study  between the above mentioned 
time-points.
 

[COMPANY_001] Confidential Page 67
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Should the investigator consider that there is an EF decrease which is clinically  relevant, 
[COMPANY_001] must be informed. The study  drug must be withheld. A discussion will take place 
with the sponsor to determine the necessary  steps to be taken to safeguard the patient.
7.2.3
Pharmacokinetics (PK)
Blood samples for pharmacokinetic assessment will be collected only for patients receiving 
midostaurin.
Routine PK blood collection will be completed at each visit;  
[IP_ADDRESS] Routine pharmacokinetic (PK) blood collection
Trough blood samples must be taken prior to midostaurin administration, refer to Table 7-8
for collection schedule . A pharmacokinetic collection applies only to patients randomized to 
the midostaurin treatment arm.
Patients are instructed to bring their medication with them during their weekl y visits and not 
to eat prior to their visit. After the trough/pre -dose PK samples are collected on the 
visit day, 
patients will then be instructed to take midostaurin following food intake.
The collection date and time of all samples must be documented on the Routine PK blood 
collection eCRF p age in addition to the date and time of dosing.
Refer to the CPKC412AUS23 Laboratory Manual for detailed instructions for the collection, 
handling, and shipment of PK samples.
Table 7-8 Routine pharmacokinetic blood collection log
Treatment 
Period or CycleDay Scheduled Time 
PointPK Sample No Sample Volume
1 1 Pre-dose/0h 101 3 mL
1 15 Pre-dose/0h 102 3 mL
2 1 Pre-dose/0h 103 3 mL
3 1 Pre-dose/0h 104 3 mL
4 1 Pre-dose/0h 105 3 mL
5 1 Pre-dose/0h 106 3 mL
6 1 Pre-dose/0h 107 3 mL
7 1 Pre-dose/0h 108 3 mL
8 1 Pre-dose/0h 109 3 mL
9 1 Pre-dose/0h 110 3 mL
10 1 Pre-dose/0h 111 3 mL
11 1 Pre-dose/0h 112 3 mL
12 1 Pre-dose/0h 113 3 mL
 

[COMPANY_001] Confidential Page 68
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
7.2.4 Biomarkers
[IP_ADDRESS] Central determination of FLT3 ITD status
In this study , patients are permitted to enroll based on the locally  known FLT3 -ITD mutation 
status which was determined at diagnosis. In order to establish the concordance of the original 
FLT3 ITD mutation status with that which is determined centrally  using a fully  characterized 
 

[COMPANY_001] Confidential Page 69
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
and analytical validated assay , FLT3-ITD mutation status will be re-assessed using remainin g 
historical material, if available, from the original diagnostic specimen. All patients will be 
asked to provide a historical sample of tissue at the time from which they  had confirmation of 
their diagnosis. The specimens which may be used for this purpose include stored frozen 
mononuclear cells or DNA if available .
 

[COMPANY_001] Confidential Page 70
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
 

[COMPANY_001] Confidential Page 71
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
 

[COMPANY_001] Confidential Page 72
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
 

[COMPANY_001] Confidential Page 73
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained.
Patients whose FLT3 -ITD status is known will sign the main stud y ICF.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Except for screen failures, Adverse events that begin or worsen after informed consent should 
be recorded in the Adverse Events eCRF. Conditions that were alread y present at the time of 
informed consent should be recorded in the Relevant Medical History /Current Medical 
Conditions page of the pati ent’s eCRF. Adverse event monitoring should be continued for at 
least 30 days (or 5 half-lives, whichever is longer) following the end of treatment as defined 
in Section 7.1.3. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Advers e Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.0.
If CTCAE grading does not exist for an 
adverse event, the severit y of mild, moderate, severe, 
and life -threatening, corresponding toGrades 1 -4, will be used. CTCAE Grade 5 (death) will 
not be used in this study ; rather, information about deaths will be collected on the 
EOT/SEC/Survival I nformation eCRFs.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or betw een visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be 
evaluated to determine:
1.The severit y grade (CTCAE Grade 1 -4)
2.Its du ration (Start, End or Ongoing )
3. Its relationship to the study  treatment (Reasonable possibility  that AE is related: No,
Yes, investigational treatment, Yes, the study  treatment (non -investigational), Yes, both 
and/or indistinguishable)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
 

[COMPANY_001] Confidential Page 74
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1.
All adverse events should be treated appropriately . If a concomitant 
medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, andassessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by [CONTACT_230784] a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with findi ng of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.[ADDRESS_277889] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatment), should be recorded on the Adverse Events eCRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found. When an abnormal laboratory  or test result corresponds to a 
sign/sy mptom of an already  reported adverse event, it is not necessary  to separately  record the 
lab/test result as an additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required by [CONTACT_64103], by [CONTACT_108], be an 
adverse event and must be reported as such.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
 

[COMPANY_001] Confidential Page 75
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospi[INVESTIGATOR_1081],
Note that hospi[INVESTIGATOR_14944]:
Rout ine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent
Social reasons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_230745] a SAE given above 
is not a serious adverse event
8.2.[ADDRESS_277890] be reported to [COMPANY_001] within 24 hours of l earning of its occurrence.
Any SAEs experienced after this 30 days period (or 5 half-lives) whichever is longer) should 
only be reported to [COMPANY_001] if the investigator suspects a causal relationship to the study  
treatment. Recurrent epi[INVESTIGATOR_1841], complication s, or progression of the initial SAE must be 
reported as follow -up to the original epi[INVESTIGATOR_5319] 24 hours of the investigator receiving the 
follow -up information. An SAE occurring at a different time interval or otherwise considered 
completely  unrelated to a previously  reported one should be reported separately  as a new 
event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and send the completed, signed form by  [CONTACT_87109] 2 4 hours to the oncology 
[COMPANY_001] Drug Safety  and Epi[INVESTIGATOR_623]  (DS&E) department.
The telephone and telefax number of the contact [CONTACT_230785][INVESTIGATOR_623]  (DS&E), specific to the site, are listed in the investigator folder 
provided to each site. The original copy of the SAE Report Form and the fax confirmation 
sheet must be kept with the case report form documentation at the study  site.
Follow -up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow -up to the previously  
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
 

[COMPANY_001] Confidential Page 76
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
progression of the original event should be reported as a follow -upto that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated, whether the blind was broken or not, and whether the 
patient continued or withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure (new occurrence) and 
is thought to be related to the [COMPANY_001] study  treatment, an oncology  [COMPANY_001] Drug Safet y and 
Epi[INVESTIGATOR_623]  (DS&E) department associate may urgentl y require further information from 
the investigator for Health Authority  reporting. [COMPANY_001] may need to issue an Investigator 
Notification (IN), to inform all investigators involved in any study with the same drug that 
this SAE has been reported. Suspected Une xpected Serious Adverse Reactions (S[LOCATION_003]Rs) will 
be collected and reported to the competent authorities and relevant ethics committees in 
accordance with Directive 2001/20/EC or as per national regulatory  requirements in 
participating countries.
8.[ADDRESS_277891] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_5373][INVESTIGATOR_230746]
t (DS&E). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
In addition, pregnancy  outcomes must be collected for the female partners of any males who 
took study  treatment in this study . Consent to report information regarding these pregnancy 
outcomes should be obtained from the mother.
8.6 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 
Brochure. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
 

[COMPANY_001] Confidential Page 77
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
8.7 Data Monitoring Committee
No Data Monitoring Committee (DMC) will be used in this trial since this is a double -arm, 
open label study . Safet y data will be monitored by [CONTACT_230786] n 
with the independent review committee ( IRC).
8.8 Independent Review committee
The Independent review committee (IRC) will consist of 3 to 5 physicians that aretransplant 
experts not participating in the trial.
The IRC will ensure transparent management of the study  according to the protocol through 
recommending and approving modificati ons as circumstances require. The IRC will complete 
a safety  review of the initital 10, 20, and 30 patients on SOC or SOC + midostaurin 
complet ingat least 3 cycles or discontinued. Additional patients may be reviewed up to 
complete trial enrollment at theIRC’s discretion. The IRC will review safety  information to 
include (but not limited to) adverse events, serious AEs, lab parameters, bone marrow results 
 in addition to protocol amendments as appropriate. Together with the 
clinical trial team, the IRC will also develop recommendations for publications of study  
results including authorship rules. The details of the role of the Independent Review
Committee will be defined in a Independent Review Committee charter.
[ADDRESS_277892] of the following:
What protected hea lth information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the 
subject experienced an y new or worsened AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
 

[COMPANY_001] Confidential Page 78
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protoc ol and eCRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study  drug is 
being stored, dispensed, and accounted for according to specifications. Key study personnel 
must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. A ll information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Addit ional checks of the consistency  of the source data with the 
eCRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
The designated investigator staff will enter the data required by [CONTACT_230787] (eCRF). The eCRFs have been built using fully validated 
secure web-enabled software that conforms to [ADDRESS_277893] been trained. Automatic 
validation programs check for data discrepancies in the eCRFs and, allow modification or 
verification of the entered data b y the investigator staff.
The Principal Investigator [INVESTIGATOR_217914], accurate, and that e ntry and updates are performed in a timely  manner.
Results from FLT3 mutation analy sis, , PK sampling  
 will be centrally  analy zed and the data will be transferred to [COMPANY_001] (or designated 
CRO) upon completion of anal ysis.
9.4 Database management and quality  control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432] . Electronic data queries stating the nature of the problem and 
requesting clarif ication will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff is required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using 
the WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical 
 

[COMPANY_001] Confidential Page 79
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
classification system. Medical history /current medical conditions and adverse events will be 
coded using the Medical dictionary  for regulatory  activities (MedDRA) terminology .
Biomarker and PK samples will be processed centrall y and the results will be sent 
electronically  to [COMPANY_001] (or a designated CRO).
Diary  data will be entered onto a paper diary  by [CONTACT_102]. Planned and or changes in 
dosing will be captured into the eCRF.
Screening, randomization and enrollment data changes will be tracked using an Interactive 
Web Response (IWRS) . The system will be supplied by a vendor(s), who will also manage 
the database. The data will be sent electronically
 to [COMPANY_001] personnel (or designated CRO).
At the conclusion of the study , the occurrence of any protocol violations will be determined. 
After these actions have been completed and the data has been verifie d to be complete and 
accurate, the database will be declared locked. Authorization is required prior to making any 
database changes to locked data .
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_5322].
[ADDRESS_277894] deviation, median, 25thand 
75thpercentile s, minimum and maximum will be presented.
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all randomized patients. According to the intent to 
treat (ITT) principle, patients will be analyzed according to the treatment arm (SOC +/-
midostaurin) they  have been assigned to during the randomization procedure.
10.1.[ADDRESS_277895] one 
dose of midostaurin during the study  will be allocated to the SOC + midosta urin treatment 
arm. Patients randomized to the SOC + midostaurin arm but who never received midostaurin 
will be allocated to the SOC treatment arm .
10.1.3 Per-Protocol Set
The Per Protocol Set (PPS) consists of all patients from the Full Analy sis Set without any 
major protocol deviations. Protocol deviations leading to the exclusion of from the PPS will 
 

[COMPANY_001] Confidential Page 80
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
be specified in the study  Validation and Planning (VAP) and Report and Analy sis Plan (RAP) 
documents prior to database lock .
10.1.4 Pharmacokinetic A nalysis Set
The Pharm acokinetic Set (PK Set) comprises all patients that have been administered at 
least one dose of midostaurin and that have provided at least one evaluable PK sample.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data (including disease characteristics) will be listed and 
summarized by  [CONTACT_230788].
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], 
compliance)
Concomitant medications and significant non-drug therapi[INVESTIGATOR_230747] y set.
10.3.1 Study medication
The study  drug (midostaurin) administration will be summarized. The number of treated 
patients, number of patients who had dose reduction/interruption and the dur ation of treatment 
will be presented.
The duration 
includes the periods of temporary  interruption (of any component of the study 
treatment for an y reason).
The safet y population will be used for all above mentioned tables and listings.
10.3.2 Concomitant therapie s
Concomitant medications and non -drug therapi[INVESTIGATOR_230748] y with the study  drugs will 
be listed and summarized by [CONTACT_84304], preferred term and treatment arm by [CONTACT_230789]. These summaries will include medications starting on or 
after the start of study  treatment or medications starting prior to the start of study  treatment 
and continuing after the start of study  treatment.
Any prior concomitant medications or significant non-drug therapi[INVESTIGATOR_230749].
The safet y population will be used for all above mentioned concomitant medication tables and 
listings.
10.4 Primary  objective
10.4.1 Relapse free survival
The primary  endpoint is relapse free survival (RFS), defined as thetime from transplant to 
relapse or death due to the disease [ADDRESS_277896] transplant . If a patient has more than one 
event (e.g. relapse then death) then the earliest date will be taken into account.
 

[COMPANY_001] Confidential Page 81
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
10.4.[ADDRESS_277897] RFS over time in each treatment arm. Median 
survival will be obtained along with 95% CI calculated using the method of Brookmey er & 
Crowley . Kaplan -Meier estimates with 95% CI will be summarized every 6 month using
Greenwood’s formula for the standard error of the Kaplan -Meier estimate. The primary 
objective is related to the Kaplan -Meier estimate at [ADDRESS_277898] Ratio (HR SOC+Midaustorin/SOC ) and associated Wald 95% 
Confidence Interval (CI).The primary  anal ysis will be performed on the FAS.
10.4.3 Handling of missing values/censoring/discontinuations
Patients alive in remission at the time of the data cut-off point used for the analysiswill have 
RFS censored at the time of last measurement prior to the data cut-off point. The number of 
patients having an event and number of patients censored will be summarized. A summary  of 
reasons censoring will be pr ovided b y treatment arm.
[COMPANY_001] AML guidance and the FDA guideline on endpoints (Clinical Trial Endpoints for the 
Approval of Cancer Drugs and Biologics, 2007) will not consider a relapse event if observed 
after two or more consecutive missing assessment s and will censor the RFS and DFS at the 
last adequate assessment date.
10.4.4 Supportive analy ses
The primary  anal ysis will be repeated on the PP Set as a supportive anal ysis.
In addition to that, a sensitivity  analysis will be performed on RFS using the time from 
randomization as reference time-point instead of the time from transplant.
The same statistical analy ses as the previous one described Section 10.4.2 will be performed 
on this variable.
This sensitivity  anal ysis will be performed on the FAS.
10.5 Secondary  objectives
10.5.1 Key secondary  efficacy  evaluation
The secondary  efficacy  variables include:
Disease Free Survival (DFS)
Relapse Free Survival (RFS)
Overall Survival (OS)
DFS is defined as the time from transplant to relapse or death from any cause. RFS is defined 
as the time from transplant to relapse or death due to the disease. OS is defined as the time 
from transplantation to the date of death from any cause. Follow up will continue until all 
patients have been followed for [ADDRESS_277899] 
withdrawn from the study prior to that time.
 

[COMPANY_001] Confidential Page 82
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Kaplan -Meier plots will be used to depi[INVESTIGATOR_230750]. Median survival will be obtained along with 95% CI calculated using the 
method of Brookmey er & Crowley . Kaplan -Meier estimates with 95% CI will be summarized 
every  6
 month using Greenwood’s formula for the standard error of the Kaplan -Meier 
estimate.
In addition to the Kaplan -Meie r estimates, Cox proportional hazards models will be used to 
provide estimates of the Hazard Ratio (HR SOC+Midaustorin/SOC ) and associated Wald 95% 
Confidence Interval (CI) for each secondary  endpoint.
These analy ses will be performed on the FAS.
10.5.2 Safety  objectiv es
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_111788], the Safety  Set (SS) will be used. All listings and tables will be 
presented b y treatment group.
The safet y summary  tables will include only “on-treatment” assessments. On treatment
assessments will be considered as:
SOC arm (whichever comes first):
From randomization until discontinuation, relapse or completion of treatment phase 
(12cy cles) + 
30 day s
SOC + PKC arm:
From first intake of stud y drug to last intake of study drug + 30 day s
Safety  will be assessed by [CONTACT_230790] (CTCAE) 
version 4.0. Incidence of adverse events (AEs), serious adverse events (SAEs), changes from 
baseline in clinicall y notable changes in vital signs and CTC grading for laboratory  results 
(hematology , blood chemistry , ECGs) will be reported.
[IP_ADDRESS] Adverse events (A Es)
Summary  tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on-treatment period, the treatment -emergent AEs. However, all safety data 
(including those from the pre and post-treatment periods) will be listed and those collected 
during the pre -treatment and post -treatment period are to be flagged.
The incidence of treatment- emergent adverse events (new or worsening from baseline ) will be 
summarized by [CONTACT_30826], severit y (based on CTCAE grades), 
type of adverse event, relation to study  treatment by  [CONTACT_1570].
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by [CONTACT_5380] b y type of adverse event and treatment group.
[IP_ADDRESS] Laboratory  abnormalities
All laboratory  values will be converted into SI units and the severit y grade calculated using 
Common Toxicity  Criteria for Adverse Events (CTCAE).
 

[COMPANY_001] Confidential Page 83
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Shift tables using CTC grades to compare baseline to the worst post-baseline value will be 
produced for hematology  and biochemistry  laboratory  parameters with CTC grades . In 
addition, shift tables using laboratory  normal ranges to compare baseline to the worst post-
baseline value will be produced for other parameters without CTC grades, if any (Ranges: 
Low, Normal, High).
All laboratory  values will be listed by [CONTACT_230791]. Separate listings will 
display  notable laboratory  abnormalities (i.e. newly  occurring CTCAE grade 3 or 4 laboratory 
toxicities).
[IP_ADDRESS] Other safety  data
Summary  statistics for data from other tests will be provided, notable values will be flagged, 
and an y other information collected will be listed as appropriate.
Descriptive summary  statistics will be provided for data for:
ECG
shift table baseline to worst on- treatment result for overall assessments
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs and weight
Summary  statistics of raw data and change from baseline values (means, medians, standard 
deviations), newl y occurring or worsening abnormalities of vital signs and weight.
Listings with flagged notable values and any other information collected will be provided as 
appropriate.
[IP_ADDRESS] Tolerab ility
To determine whether midostaurin can be administered at a daily  dose of 50mg twice daily at 
least 80% of the time to 50% or more of patients during the first [ADDRESS_277900]
[IP_ADDRESS] Non- relapse mortality
NRM is defined as the duration between the date of transplant and the date of patient death 
due to reasons other than relapse.
Kaplan -Meier plots will be used to depi[INVESTIGATOR_230751]-relapse mortality  over time in each treatment 
arm. Median survival will be obtained along with 95% CI calculated using themethod of 
Brookmey er & Crowley . Kaplan -Meier estimates with 95% CI will be summarized every  6 
month using Greenwood’s formula for the standard error of the Kaplan -Meier estimate.
In addition to the Kaplan -Meier estimates, Cox proportional hazards models will be used to 
provide estimates of the Hazard Ratio (HR SOC+Midaustorin/SOC ) and associated Wald 95% 
Confidence Interval (CI) for each secondary  endpoint.
These analy ses will be performed on the FAS.
 

[COMPANY_001] Confidential Page 84
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
10.5.3 Pharmacokinetics
Descriptive statistics will be presente d for all concentration data of midostaurin and its 
metabolites obtained by [CONTACT_51199], and/or Day and time-point. These include geometric and 
arithmetic means, standard deviation (SD), and coefficient of variance (CV).
[IP_ADDRESS] FLT3 ITD mutation status
Descriptive statistics of FLT3 ITD mutation status centrall y assessed will be provided.
[IP_ADDRESS] Data handling principles
Missing concentration values will be reported as is in data listings. Concentration values 
below Lower Limit of Quantitation (LLOQ, BLLOQ) will be handled as zero in summar y 
statistics, and reported as is in data listings. Any missing pharmacokinetic parameter data will 
not be imputed.
10.5.[ADDRESS_277901] a statistical difference 
between the two arm s.The sample size for the trial was chosen ;[ADDRESS_277902] separate estimates of the primary  endpoint relapse free survival .Powering of the trial 
 

[COMPANY_001] Confidential Page 85
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
is not feasible considering the rare nature of F LT3-ITD mutant AML receiving a HSCT. W ith 
a 22-25% FLT3 -ITD mutation rate and approximately  25% rate of HSCT, estimated from the 
ongoing Phase III study (
2301, CAL GB [ZIP_CODE], Ratify ), more than [ADDRESS_277903] of Care (SOC), in this study  provides the first prospective subjects 
treated at the same centers in the same timeframe which will allow an estimate of treatment 
effect which can be used to design a larger trial. There are no published sets of prospective, 
FLT3 -ITD AML outcomes after transplantation
If the two arms were compared, the following gives the power that could be achieved under 2 
scenarios of relapse rate with 30 patients per treatment arm.
Scenario 1: Assuming a 3 0% relapse rate in the SOC arm
Scenario 2: Assuming a 50% reduction with midostaurin (experimental arm)
i.e., 15% relapse rate in the experimental arm, a sample size of [ADDRESS_277904] the reduction with 71% power. This calculation is based on one- sided type I error rate 
of 20%. The power would be 81% if we assume relapse rate to be even lower at 12% keepi[INVESTIGATOR_230726].
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is 
required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/ REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent or, if incapable of
doing so, after such consent has been provided by a legally  acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be 
informed about the study  to the extent possible given his/her understand ing. If the patient is 
 

[COMPANY_001] Confidential Page 86
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
capable of doing so, he/she should indicate assent by  [CONTACT_230792] a separate assent form.
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a subject’s Informed 
Consent was actuall y obtained will be captured in their CRFs.
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in 
Section 4.3.
11.5 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
11.[ADDRESS_277905] keepi[INVESTIGATOR_5324], in 
compliance with Section 
4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protecti on of confidentiality of subjects. As part of participating in a 
[COMPANY_001] -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by [CONTACT_1289], to copy) clinical 
 

[COMPANY_001] Confidential Page 87
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstr uction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_16213], microfiches, photographic negatives, microfilm or magnetic media, x-rays, and 
subject files and records kept at the pharmacy , at the laboratories, and medico- technical 
departments involved in the clinical trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study  electronic case report form (eCRF) is the primary 
data collection instrument for the study . The investigator should ensure the accuracy , 
completeness, legibility , and timeliness of the data reported in the eCRFs and all other 
required reports. Data reported on the eCRF, that are derived from source documents, should 
be consistent with the source documents or the discrepancies should be explained. All data 
requested on the eCRF must be entered . Any missing data must be explained. For electronic 
eCRFs an audit trail will be maintained b y the s ystem.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
[CONTACT_64122]/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinica l Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines
11.[ADDRESS_277906] ensure anon ymity of the patients; patients must not be identified by 
[CONTACT_64123]. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.9 Financial disclosures
Financial disclosures should be provided by [CONTACT_230793]
t or evaluation of patients at the site - prior to study  start.
 

[COMPANY_001] Confidential Page 88
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
[ADDRESS_277907] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.[ADDRESS_277908] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviati on from the 
protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. [LOCATION_006] requires the notification of 
urgent safet y measures within 3 days) but not later th an 10 working day s.
 

[COMPANY_001] Confidential Page 89
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
13 References (available upon request)
American Cancer Society (2011) Cancer Facts & Figures. Atlanta, GA.
Barry  EV, Clark JJ, Cools J, et al (2007) Uniform sensitivity  of FLT3 activation loop mutants 
to the ty rosine kinase inhibitor midos taurin. Blood. 110(13):4476 - 4479.
Bornhauser M, Illmer T, Schaich M ,et al (2007) Improved Outcomes after stem -cell 
transplantation in FLT3 -ITD
-positive AML. Blood. 109 (5): 2264-65.
Brunet S, Labopin M, Esteve J, et al (2012) Impact of FLT3 Internal Tandem Duplication on 
the outcome of related and unrelated hematopoietic transplantation for adult acute m yeloid 
leukemia in first remission: a retrospective anal ysis. J Clin Oncol . 30(7). 735
-741.
Brunet S, Labopin M, Esteve J ,et al (2012) Impact of FLT3 Internal Tandem Duplication on 
theOutcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute 
Myeloid Leukemia in First Remission: A Retrospective Anal ysis. J Clin Oncol. 30: 735
-741.
Burnett A (2011) Acute My eloid Leukemia in Postgraduate Hematology . Sixth Edition. 
Wiley -blackwell publishing. Edited by  A Victor Hoffbrand. West Sussex [LOCATION_006].
Burnett A, Wetzler M, Lowenberg B
(2011) Therapeutic Advances in Acute My eloid 
Leukemia. J Clin Oncol . 29:487 -494.
 
del Corral A, Dutriex C, Huntsman
-Labed A ,et al (2012) Midostaurin does not prolong 
cardiac repolarization defined in a thorough electrocardiogram trial in healthy  volu nteers 
Cancer Chemotherap y and Pharmacology ; 69(5): 1255 -
1263.
Estey  E (2010) Understanding and Managing Ultra High -Risk Hematological Malignancies: 
High C ytogenetic or Molecular Genetic Risk Acute My eloid Leukemia. Hematology  
2010:474
-480.
Fernandez HF, S un Z, Yao X, et al (2009) Anthracycline Dose INtenstification in Acute 
Myeloid Leukemia. New England Journal of Medicine ; 361:1249-1259.
 
Fischer T, Stone R, DeAngelo D, et al (2010) Phase IIB trial of oral midostaurin (PKC412), 
the FMS -like ty rosine kinase 3 receptor (FLT3), and multi- targeted kinase inhibitor, in 
patients with acute m yeloid leukemia and high risk my elodysplastic s yndrome with either 
wild ty pe or mutated FLT3. J Clin Oncol; 28(28): 4339 -4345.
Flockhart DA (2009) Drug Interactions: Cy tochrome P450 Drug Interaction Table. Indiana 
University  School of Medicine (2007) Version 5.0 released on Jan 12, 2009.
http://medicine.iupui.edu/flockh art/table.htm.
Gale R, Hills R, Kottardis P, et al (2005) 
No evidence that FLT3 s tatus should be considered 
as an indicator for tranplantation in acute m yeloid leukemia (AML): an analysis of 1135 
patients excluding acute promy elocy tic leukemia, from the [LOCATION_006] MRC AML10 and 12 trials. 
BLOOD; 106(10), 3658–65.
 

[COMPANY_001] Confidential Page 90
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Gale RE, Green C, Allen C, et al (2008) The impact of FLT3 internal tandem duplication 
mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young 
adult patients with acute my eloid leukemia. Blood ;111:2776 -
2784.
Gale RE, Hills R, Wheatley K, et al ( 2007) Still a need for more robust evidence that 
FLT3/ITD status should influence the decision to proceed to transplantation in AML  patients 
BLOOD; 109(5) , 2265 - 2265.
Gotlib J, Kluin
-Nelemans H, George T, et al (2012) KIT Inhibitor Midostaurin in Patients 
with Advanced S ystemic Mastocy tosis: Results of a Planned Interim Analysis of the Global 
CPKC412D2201 Trial. Blood. 2010;116:[abstract 316] .
Hayakawa F, Towatari M, Kiy oi H, et al (2000) Tandem -duplicated Flt3 constitutively  
activates STAT5 and MAP kinase and introduces autonomous cell growth in IL -
3-dependent 
cell lines. Oncogene;19(5):624-631.
Kayser S, Schlenk RF, Londono MC, et al (2009) Insertion of FLT3 internal tandem 
duplication in the ty rosine kinase domain -1 is associated with resistance to chemothera py and 
inferior outcome. Blood;114(12):2386-2392.
Kindler T, L
ipka D, Fisher T (2010 ) FLT3 as a therapeutic target in AML: still challenging 
after all these years. Blood;116:5089-5102.
Kiyoi H, Naoe T, Nakano Y, et al (1999) Prognostic implication of FLT3 and N -RAS gene 
mutations in acute my eloid leukemia. Blood;93(9):3074 -3080.
Kiyoi H, Towatari M, Yokota S, et al (1998) Internal tandem duplication of the FLT3 gene is 
a novel modality  of elongation mutation which causes constitutive activation of the produ
ct. 
Leukemia;12(9):1333 -1337.
Kottaridis PD, Gale RE, Frew ME, et al (2001) The presence of a FLT3 internal tandem 
duplication in patients with acute m yeloid leukemia (AML) adds important prognostic 
information to cy togenetic risk group and response to the first cy cle of chemotherapy : 
analysis of 854 patients from the [LOCATION_008] Medical Research Council AML  10 and 12 
trials. Blood;98:1752-1710.
 
 
Manley  PW, Boulton C, Caravatti G, et al ( 2003 ) Preclinical profile o f PKC412 (midostaurin) 
as an FLT3 inhibitor for the therap y of AML. Presented at the American Association for 
Cancer Research Annual Meeting, Washington, DC, July  11-14, 2003 (poster 1004).
Meshinchi S, Alonzo TA, Stirewalt DL , et al (2006) Clinical implic ations of FLT3 mutations 
in pediatric AML. Blood;108(12):3654 -3661.
Meshinchi S, Arceci RJ, Sanders JE, et al (2006) Role of allogeneic stem cell transplantation 
in FLT3/ITD -positive AML . Blood;108:400; author repl y 400 -
401.
 

[COMPANY_001] Confidential Page 91
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Metabolism and Transport (2011) Drug Interaction Database, Version 4.0, University of 
Washington, Department of Pharmaceutics (2008) www.druginteractioninfo.org (Last update: 
Jan, 2011) .
Metzelder S,Wang Y,Wollmer E,et al (2009) Compassionate use of sorafenib in FLT3- ITD-
positive acu te my eloid leukemia: sustained regression before and after allogeneic stem cell 
transplantation. Blood;113(26):6567-6571.
NCCN Guidelines v1. (2012) National Comprehensive Care Network. NCCN Clinical 
Practice Guidelines in Oncology  –Acute M yeloid L eukemia . Version 2.2012.
Pravtz K, Sato T, Murphy  K, et al (
2010 )FLT3 -mutant allelic burden and clinical status are 
predictive of response to FLT3 inhibitors in AML. Blood; 115(7):1425- 1432.
Ravandi F, Burnett A, Agura E, et al (2007) Progress in the Treatment o f Acute My eloid 
Leukemia. Cancer;110:1900 –10.
Roesel J, Fabbro D, Mestan J, et al (2004) Antiproliferative activity  of PKC412 in various 
human AML  cell lines RD -
2004-[ZIP_CODE].
 
Schlenk RF, Dohner K, Krauter J, et al (
2008 )Mutations and treatment outcome in 
cytogeneticall y normal acute myeloid leukemia. N Engl J Med;358:1909-1918.
Schnittger S, Schoch C, Dugas M, et al (2002) Analy sis of FLT3 length mutations in 1003 
patients with acute m yeloid leukemia: correlation to cy togenetics, FAB subty pe, and 
prognosis in the AMLCG study  and usefulness as a marker for the detection of m inimal 
residual disease. Blood ;100(1):59 -
66.
Sora F,Chiusolo P,Metafuni E,et al (2011) Sorafenib for refractory  FMS -like ty rosine kinase 
receptor -3 (FLT3/ITD+) acute m yeloid leukemia after allogenic stem cell 
transplantation. Leuk Res;35(3):422 -423.
Stone RM, DeAngelo DJ, Klimek V, et al (2005) Patient s with acute my eloid leukemia and an 
activating mutation in FLT3 respond to a small -molecule FLT3 ty rosine kinase inhibitor, 
PKC412. Blood; 2005;105:54 -60.
Stone RM, Fischer T, Paquette R, et al (2009) A phase 1b study  of midostaurin (PKC412) in 
combinatio n with daunorubicin and cy tarabine induction and high- dose cy tarabine 
consolidation in patients under age 61 with newl y diagnosed de novo acute my eloid leukemia: 
overall survival of patients whose blasts have FLT3 mutations is similar to those with 
wildty pe FLT3. ASH [ADDRESS_277909], Blood, Vol 114.
Stone RM, Fischer T, Paquette R, et al (2012) Phase IB stud y of FLT3 kinase inhibitor 
midostaurin with chemotherap y in younger newl y diagnosed adult patients with acute m yeloid 
leukemia. Leukemia 26, 2061 -
2068.
Thiede C, Steudel C, Mohr B, et al (
2002) Analy sis of FLT3 -activating mutations in 979 
patients with acute m yelogenous leukemia: association with FAB subt ypes and identification 
of subgroups with poor prognosis. Blood ;99(12):4326 -4335.
Utz I , Spi[INVESTIGATOR_230752] M, Ry bczy nska M, et al (1998) Reversal of multidrug resistance by  
[CONTACT_230794]41251 and CGP42700. I nt. J. Cancer.; 77: 64 -
9.
 

[COMPANY_001] Confidential Page 92
Amended Protocol Version 02 ( Clean ) Protocol No. CPKC412AUS23
Van den Brink M, Porter D, Giralt S ,et al (2010) Relapse after allogeneic hematopoietic cell 
therap y. Biol Blood Marrow Transplant . 16:S138- S145.
Weisberg E, Boulton C, Kelly  LM, et al (2002) Inhibition of mutant FL T3 receptors in 
leukemia cells b y the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell; 1: 433 -
443.
Whitman SP, Archer KJ, Feng L, et al (2001) Absence of the wild -type allele predicts poor 
prognosis in adult de novo acute m yeloid leukemia with normal cytogenetics and the internal 
tandem duplication of FLT3: a cancer and leukemia group B stud y. Cancer Res;61(19):7233 -
7239.
Yanada M, Matsuo K, Emi N, et al (2005) Efficacy  of allogeneic hematooietic stem cell 
transplant depends on cytogenetic risk for AML is first disease remission: a meta -analysis. 
Cancer; 103: 1652 -58.
Yin O, Wang Y, Lanza C, et al (2008) Pharmacokinetics (PK) and pharmacody namics (PD) 
of midostaurin (PKC412) in patients with acute myeloid leukemia (AML). J Clin Oncol 
26:388s, (abstr 7064) .
 
